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Attaching and effacing Escherichia coli are significant diarrhoeal pathogens that can 
spread between humans or via animal reservoirs. One important virulence factor is a 
large multifunctional protein called lymphostatin (LifA), which has been reported to 
inhibit the mitogen-stimulated proliferation of lymphocytes and mediate adherence 
to epithelial cells. Mutants of Shiga toxin-producing E. coli lacking lifA are 
significantly impaired in their ability to colonise cattle. Little is known about the 
mode of action of LifA, however in silico analysis has identified a putative 
glycosyltransferase domain homologous to that of large clostridial toxins (LCTs). A 
shortened form of LifA has been shown to be Type III secreted, however it is not 
known if this is true for the full-length protein. Type III secretion assays using the 
prototype enteropathogenic E. coli strain E2348/69 and isogenic lifA and Type III 
secretion system mutants confirmed that LifA can be secreted through this transport 
system. Working in collaboration, I was also able to demonstrate that LifA can be 
purified in an active form that binds uridine diphosphate-N-Acetylglucosamine 
(UDP-GlcNAc) but not UDP-glucose. In order to probe the importance of a putative 
catalytic DXD motif within the glycosyltransferase domain, an in-frame DXD to 
AAA substitution mutant of full-length LifA was constructed. The ability of the 
purified wild-type and mutated protein to bind UDP sugars and inhibit bovine T cell 
proliferation were then examined. DXD-AAA substitution resulted in loss of binding 
of UDP-GlcNAc and the ability to inhibit mitogenic stimulation of bovine T cells, 
without obvious changes to the biophysical properties of the protein. Unlike LCTs, 
wild-type LifA did not appear to be directly cytotoxic to HeLa or Jurkat cells using a 
fluorescence-based assay for release of lactate dehydrogenase. Future studies will 
seek to define the cellular targets and consequences of GlcNAc modification by 
lymphostatin, as well as identifying other possible mechanisms of secretion and its 
ability to act as an adhesin. 
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Chapter 1: Introduction 
 
1.1 Escherichia coli 
 
 Escherichia coli are Gram-negative facultative anaerobes that are commonly 
found living in the environment or as commensals in the gastrointestinal tract of 
animals and man (Winfield and Groisman, 2003). The survival of environmental E. 
coli populations is dependent on a number of factors including nutrient availability, 
temperature, the presence of toxic substances and predation (Carlucci and Pramer, 
1959; Faust et al, 1975; Gerba and McLeod, 1976). The bacteria do not survive for 
long in temperate environments (Temple et al, 1980) and the population appears to 
be kept constant by the arrival of new bacteria from animal hosts (Savageau, 1983). 
However, several studies have shown that E. coli is capable of entering a viable but 
non-culturable state, meaning that the cells enter a state in which they are 
metabolically active but cannot be cultured by known laboratory methods, due to 
environmental stresses (Reissbrodt et al, 2002; Asakura et al, 2008; Li et al, 2014). 
Despite its poor survival in temperate climates, E. coli is capable of surviving in 
nutrient rich soil and fresh water in tropical environments where there is no obvious 
sign of faecal contamination (Solo-Gabriele et al, 2000; Rivera et al, 1988; Jiménez 
et al, 1989). Due to its prevalence in mammalian faeces and its relatively short 
survival time in the environment, E. coli is used as an indicator of faecal 
contamination of drinking water (Edberg et al, 2000). Its usefulness as an indicator 
in tropical countries, however, is limited due to the prevalence of the bacteria in the 
environment in such countries (Solo-Gabriele et al, 2000; Rivera et al, 1988; 
Jiménez et al, 1989). 
 E. coli primarily exist as a commensal in the lower intestines of warm 
blooded animals and reptiles, and make up a large component of the normal gut 
microflora (Leimbach et al, 2013). Its presence is usually beneficial to its host as E. 
coli is capable of synthesising vitamin K2 (Bentley and Meganathan, 1982) and, 
along with the rest of the gut microflora, it exerts a protective effect against 
pathogenic bacteria (Hudault et al, 2001).  
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 Although normally harmless to its host, E. coli is an opportunistic pathogen 
that, through the acquisition of mobile genetic elements, can become a serious 
pathogen (Croxen and Finlay, 2010). Pathogenic E. coli strains can be divided into 
two subgroups depending on the site of infection, with diarrhoeagenic E. coli 
infecting the intestines and extraintestinal E. coli (ExPEC) infecting sites beyond the 
intestines (Croxen and Finlay, 2010; Leimbach et al, 2013). 
 
1.2 E. coli pathotypes 
 
 The diarrhoeagenic E. coli and ExPEC subgroups can be further divided into 
distinct pathotypes based on particular characteristics. ExPEC consists primarily of 
uropathogenic E. coli, which infects the urinary tract, and neonatal meningitis E. 
coli, which infects the brain (Croxen and Finlay, 2010; Leimbach et al, 2013). Other 
pathotypes of ExPEC exist such as septicaemia-associated E. coli and avian 
pathogenic E. coli although these are less well defined (Croxen and Finlay, 2010; 
Leimbach et al, 2013). The main diarrhoeagenic E. coli pathotypes are 
enterotoxigenic E. coli (ETEC), enteroaggregative E. coli (EAEC), enteroinvasive E. 
coli (EIEC), diffusely adherent E. coli (DAEC), enteropathogenic E. coli (EPEC) and 
enterohaemorrhagic E. coli (EHEC; Croxen and Finlay, 2010; Leimbach et al, 2013). 
 ETEC is the most common cause of traveller’s diarrhoea and it is also 
important in the farming industry, particularly as a cause of acute enteritis and 
colibacillosis in young pigs and calves (Nataro and Kaper, 1998; Croxen and Finlay, 
2010). It is characterised by its adherence to enterocytes via colonisation factors and 
the secretion of heat-labile and heat-stable toxins, which cause diarrhoea (Nataro and 
Kaper, 1998; Croxen and Finlay, 2010). EAEC is the second most common cause of 
traveller’s diarrhoea and is characterised by forming biofilms on enterocytes using 
aggregative adherence fimbriae (Croxen and Finlay, 2010). EIEC, which include 
bacteria of the genus Shigella, is characterised by its facultative intracellular 
lifestyle. It achieves this by passing through microfold cells via transcytosis, 
replicating inside macrophages in the intestinal submucosa, then invading 
enterocytes from their basolateral side (Croxen and Finlay, 2010). DAEC is 
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characterised by forming diffuse attachments to enterocytes using fimbrial and 
afimbrial adhesins (Croxen and Finlay, 2010). 
 EPEC and EHEC are collectively known as attaching and effacing (A/E) E. 
coli (Croxen and Finlay, 2010; Stevens and Frankel, 2014) and are described in 
greater detail below. 
 
1.3 Attaching and effacing E. coli 
 
 A/E lesions are characterised by intimate bacterial attachment to the surface 
of enterocytes on actin-rich ‘pedestals’ and the destruction of microvilli, thereby 
disrupting the absorption of nutrients by the gut, contributing to diarrhoea (Figure 
1.1; Croxen and Finlay, 2010; Stevens and Frankel, 2014). The pedestals are also 
assembled with other cytoskeletal proteins besides actin, such as α-actinin, talin, 
ezrin and myosin light-chain (Finlay et al, 1992; Manjarrez-Hernandez et al, 1992). 
Recently, Law et al (2015) identified more than 90 proteins present in the pedestals 
formed by EPEC, 17 of which were in a significantly higher abundance than in 
uninfected cells. Actin-associated proteins such as cyclophilin A may only be present 
due to their interactions with actin, but non-actin-associated proteins such as 
transgelin may have other as yet undefined roles (Law et al, 2015). A/E lesion 
formation in E. coli is mediated by various virulence factors, which are only 







































Figure 1.1. Transmission electron micrograph of EHEC O111:H- E45035N 
forming attaching and effacing lesions on a bovine calf colonocyte. Actin rich 
pedestals can be seen as electron dense regions beneath the EHEC cells. An 
uninfected cell to the right gives a comparison of a healthy cell surface and 
microvilli. Scale bar = 1μm (taken from Stevens et al, 2002). 
 
 EPEC is a major cause of infantile diarrhoea in the developing world and 
causes both acute and chronic diarrhoea (Ochoa and Contreras, 2011). Once attached 
to an enterocyte, EPEC disrupts ion balance and water absorption resulting in 
diarrhoea (Croxen and Finlay, 2010). Sanger et al (1996) also found that EPEC are 
able to use A/E pedestals as a form of motility to travel across the surface of host 
cells at speeds of up to 0.07μm/second. EPEC strains can be further divided into 
typical EPEC, which possess bundle-forming pili (BFP), and atypical EPEC, which 
do not (Trabulsi et al, 2002). Prevalent EPEC serotypes include O55:H6, O127:H6, 
O128:H2 and O142:34 among others (Gomes et al, 1989; Trabulsi et al, 2002). The 
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genome of the prototypic EPEC strain E2348/69 consists of an ~5Mb circular 
chromosome, an ~97kb EPEC adherence factor (EAF) plasmid and a small ~6kb 
drug-resistant plasmid (Iguchi et al, 2008). The core genome is highly conserved 
with lab strains, commensal E. coli and other pathotypes of E. coli, but is broken up 
by 13 prophages and eight integrative elements (Iguchi et al, 2008). Iguchi et al, 
(2008) also identified 424 genes that were specific to EPEC E2348/69. 
 EHEC causes a zoonotic infection and ruminants are a key reservoir (Croxen 
and Finlay, 2010). Outbreaks in both the developing and developed world have been 
caused by cattle, due to faecally contaminated food or water (Ho et al, 2013). EHEC 
is responsible for haemorrhagic colitis and haemolytic uraemic syndrome in humans 
(HUS; Ho et al, 2013), which it causes by the production of one or more Shiga toxins 
(Stx; Croxen and Finlay, 2010). The pathogenesis of EHEC is similar to that of 
EPEC with the exception of the production of Stx, which acts as a cytotoxin (Croxen 
and Finlay, 2010). The most prevalent EHEC serogroups are O26, O45, O103, O111, 
O121, O145 and O157:H7 (Brooks et al, 2005). The chromosome of the prototypic 
EHEC O157:H7 strain EDL933 has a similar backbone sequence to E. coli K-12 
except for a 422kb inversion, which spans the replication terminus (Perna et al, 
2001). This backbone sequence is interrupted by 177 O-islands found in E. coli 
O157:H7 but not laboratory-adapted E. coli K-12, many of which encode known 
virulence proteins (Perna et al, 2001). There are also 18 prophages throughout the 
chromosome and various single nucleotide polymorphisms create proteins that are 
identical in size and function to E. coli K-12 homologues but overall only 25% of 
proteins are identical (Perna et al, 2001). EHEC O157:H7 also contains the pO157 
plasmid, which encodes various virulence factors (Burland et al, 1998). 
 
1.4 Major virulence factors in A/E E. coli 
 
 EPEC and EHEC produce several key virulence factors that aid their 
colonisation of human and animal hosts, many of which are required for the 




1.4.1 The locus of enterocyte effacement (LEE) 
 
 The LEE is a pathogenicity island comprising over 40 contiguous genes, 
which encode virulence factors that aid colonisation of a host, some of which are 
required for attachment and effacement (Stevens and Frankel, 2014). It is a ≥ 35kb 
locus that is conserved amongst EPEC and EHEC as well as other A/E pathogens 
including certain strains of rabbit diarrhoeagenic E. coli (RDEC), Hafnia alvei and 
the mouse pathogen Citrobacter rodentium (McDaniel et al, 1995; Deng et al, 2001). 
The GC content of the LEE is only 38.36% (Elliot et al, 1998) compared with 50.8% 
across the whole E. coli genome (Blattner et al, 1997), which is typical of 
pathogenicity islands (Hacker et al, 1997). The LEE consists of 41 open reading 
frames arranged into five polycistronic operons (Figure 1.2; Elliot et al, 1998), three 
of which are involved in the production of proteins required for the assembly of a 
Type III secretion system (T3SS; Mellies et al, 2007). 
 The LEE contains the E. coli secretion (esc)/secretion of E. coli proteins (sep) 
genes and genes that encode initimin, E. coli secreted proteins (Esps) including 
translocated intimin receptor (Tir) as well as chaperones and regulatory genes (Elliot 
et al, 1998). The 3 end of the LEE in EPEC is homologous to genes from Shigella 
sonnei (Donnenberg et al, 1997), however, the DNA sequences surrounding the LEE 
vary since it is inserted into different positions depending on the serotype and strain 
of bacteria (Ogura et al, 2009).  These variable end sequences along with the low GC 
content suggests that E. coli and other A/E pathogens have acquired this DNA from 
another species, or that it once existed as a mobile genetic element (Donnenberg et 
al, 1997). 
 The regulation of the LEE is complex, with different regulatory systems 
specific to different operons (Mellies and Lorenzen, 2014). The production of LEE 
proteins is tightly regulated by temperature and growth phase, with the most protein 
synthesis occurring at 37°C in the early logarithmic phase of growth (Rosenshine et 
al, 1996). Regulatory systems of the LEE include silencing by histone-like 
nucleoid-structuring protein, the LEE-encoded regulatory cascade, 
post-transcriptional regulation and control by phage- or plasmid-encoded regulators 




Figure 1.2. Schematic of the locus of enterocyte effacement from EHEC O157:H7 showing the five polycistronic operons  and the 
genes encoded within them (taken from Stevens and Frankel, 2014). 
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1.4.2 The Type III secretion system 
 
 T3SSs are widely used by a range of Gram-negative pathogens of animals 
and plants (Büttner, 2012). There are at least five other well characterised secretion 
systems in Gram-negative bacteria (Costa et al, 2015) but the T3SS is particularly 
important for the purpose of this study. The T3SS in A/E E. coli is encoded by the 
LEE and is composed of Esc/Sep proteins as well as EspA, B and D (Elliot 1998; 
Stevens and Frankel, 2014). It was discovered by Jarvis et al (1995), who found that 
certain LEE-encoded proteins exhibited homology to proteins encoding T3SSs in 
other bacteria. T3SSs include flagella (Büttner, 2012) but for the purpose of this 
study, it is the translocation-associated T3SS that is being referred to. This T3SS is 
akin to a molecular syringe that can inject effector proteins directly into a host cell 
(Figures 1.3 and 1.4; Büttner, 2012; Stevens and Frankel, 2014). It consists of a 
region that spans both membranes of the bacterial cell, which is connected via EscF 
to the EspA filament and the translocon, which is composed of EspB and D (Büttner, 
2012; Stevens and Frankel, 2014; Warawa et al, 1999). 
 The proteins SepL and SepD regulate the order that effector proteins are 
secreted in with mutations leading to hypersecretion of effector proteins rather than 
translocon components (Kresse et al, 2000; O’Connell et al, 2004; Wang et al, 
2008). EspZ halts effector translocation from inside the host cell, possibly by 
interacting with EspD (Berger et al, 2012; Creasey et al, 2003). The secretion of 
effector proteins via the T3SS is contact-dependent in some bacteria such as Yersinia 
(Rosqvist et al, 1994) but contact between the T3SS and host cells is not required for 
the secretion of effector proteins in E. coli (Kenny et al, 1997b). Various inhibitors 
of the T3SS have been identified, many of which are part of a family of salicylidene 
acylhydrazides that inhibit the transcription of T3SS encoding genes (Gauthier et al, 
2005; Rasko et al, 2008; Tree et al, 2009). This is in contrast to T3SS inhibitors that 
work against Shigella by interfering with T3SS protein assembly (Veenendaal et al, 
2009). Vaccines including the LEE-encoded proteins EspA, intimin and Tir as well 
as the H7 flagellin have been shown to significantly reduce the shedding of EHEC 
O157:H7 in cattle faeces (McNeilly et al, 2010), consistent with a key role for this 
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system in intestinal colonisation of cattle (Dziva et al, 2004; Naylor et al, 2005; 
Vlisidou et al, 2006). 
 
 
Figure 1.3. Schematic of the Type III secretion system showing the proteins 
required for its formation in attaching and effacing E. coli. Effector proteins are 
translocated through the needle complex spanning the inner and outer membranes, 
then the EspA filament and the transolcon composed of EspD and B into the host cell 
cytoplasm (adapted from Stevens and Frankel, 2014). 
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Figure 1.4. Schematic of EHEC adhering to an enterocyte and injecting various 
effector proteins into it via the Type III secretion system (taken from Stevens 
and Frankel, 2014). 
 
1.4.3 E. coli secretion/secretion of E. coli proteins 
 
 The Esc and Sep proteins are part of the same family but some Seps were 
renamed as Escs after Elliot et al (1998) sequenced the LEE in order to conform with 
the naming convention of homologous Yersinia proteins.  Esc/Sep proteins comprise 
the E. coli T3SS and are essential for the translocation of effector proteins (Jarvis et 
al, 1995; Stevens and Frankel, 2014). EscN is the most relevant of these proteins in 
terms of this study as an EPEC strain lacking the escN gene (Garmendia et al, 2004) 
 11 
is used as a T3SS deficient control. EscN is an ATPase that provides the energy for 
the secretion of effector proteins and the energy output of the protein increases when 
it oligomerises (Jarvis et al, 1995; Andrade et al, 2007). Two other proteins in this 
family that are important for the formation of A/E lesions are SepL and SepD, which 
act as gatekeeper proteins (Wang et al, 2008). These proteins form a complex in the 
bacterial inner membrane and SepL binds to Tir to prevent effector proteins from 
being secreted before translocator proteins such as EspA (Kresse et al, 2000; 
O’Connell et al, 2004; Wang et al, 2008). 
 
1.4.4 E. coli secreted proteins 
 
 The Esp series of proteins consists of a large number of proteins, the 
functions of some of which have been extensively studied (Stevens and Frankel, 
2014). EspA forms a hollow filamentous extension of the T3SS needle complex 
(Ebel et al, 1998; Knutton et al, 1998) that bridges the bacterial and host cells and 
allows the translocation of effector proteins such as Tir and EspB into the host cell 
(Kenny et al, 1997a; Wolff et al, 1998). EspA polymerises in a helical manner to 
form a channel that effector proteins can be secreted through (Daniell et al, 2003; 
Crepin et al, 2005). A/E E. coli lack these EspA filaments during intimate adhesion 
but the mechanism behind this is unknown (Steven and Frankel, 2014). EspB 
functions as both a component of the T3SS and an effector protein (Warawa et al, 
1999; Taylor et al, 1998). It associates with EspD to form a pore in the host cell 
plasma membrane at the end of the EspA filament (Warawa et al, 1999) but is also 
injected into host cells by the T3SS (Wolff et al, 1998). As an effector protein it 
binds to myosin and inhibits the interaction of myosin with actin, resulting in 
microvillus effacement and the inhibition of phagocytosis (Iizumi et al, 2007). EspB 
also suppresses NF-κB activation, which results in the inhibition of proinflammatory 
cytokine production (Hauf and Chakraborty, 2003), although it is unclear if this 
reflects a direct role or the requirement for EspB in injection of other effectors. 
 EspD is another Type III secreted (T3S) protein (Lai et al, 1997) that is 
translocated into host cells before forming pore complexes with EspB in host cell 
plasma membranes (Kresse et al, 1999; Warawa et al, 1999; Wachter et al, 1999). 
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EspFU, also known as Tir-cytoskeleton coupling protein (TccP), is a secreted effector 
protein of EHEC O157:H7 that is particularly important in EHEC because it binds to 
the insulin receptor tyrosine kinase substrate (IRTKS)/insulin receptor substrate p53 
(IRSp53) complex and neural Wiskott-Aldrich syndrome protein (N-WASP), 
resulting in the formation of A/E lesions (Garmendia et al, 2004; Brady et al, 2007; 
Stevens and Frankel, 2014). The homologous protein EspF has a wide range of 
functions including the disruption of mitochondrial function, cytoskeletal 
manipulation and the induction of apoptosis (Holmes et al, 2010; Stevens and 
Frankel, 2014). There are many other proteins in the Esp family but those described 
above are the major proteins, with the exception of EspF, that are required for A/E 
lesion formation. 
 
1.4.5 Non-LEE-encoded (Nle) proteins 
 
 In addition to the LEE-encoded effector proteins, the Nle proteins are also 
secreted effector proteins but are encoded outwith the LEE (Stevens and Frankel, 
2014). NleA disrupts tight junction integrity between enterocytes by inhibiting 
protein trafficking via COPII-dependent pathways, resulting in a breakdown of the 
intestinal epithelial barrier and causing diarrhoea (Thanabalasuriar et al, 2010). NleB 
is an immunomodulatory protein that disrupts tumour necrosis factor signalling in 
infected cells including NF-κB signalling, which in turn prevents the expression of 
pro-inflammatory cytokines, and apoptosis (Li et al, 2013). NleC, E and H also 
interfere with NF-κB signalling in different ways (Stevens and Frankel, 2014). NleC 
is a zinc metalloprotease that degrades NF-κB (Pearson et al, 2011) and NleE 
prevents the degradation of the NF-κB inhibitor IκB (Nadler et al, 2010). NleH 
interferes with NF-κB by both preventing the phosphorylation and translocation of 
NF-κB transcriptional complexes and by suppressing IκB degradation (Stevens and 
Frankel, 2014) as well as inhibiting apoptosis by binding the protein Bax inhibitor-1 
(Hemrajani et al, 2009). NleD is another zinc metalloprotease that cleaves the host 
proteins JNK and MAPK to inhibit both apoptosis and pro-inflammatory cytokine 
expression via AP-1 activation (Baruch et al, 2011). NleF prevents apoptosis of 
infected cells by binding to caspases (Blasche et al, 2013) and the NleG acts in a 
 13 





 Intimin is a 94kDa protein (Yu and Kaper, 1992) that is encoded by the E. 
coli attaching and effacing (eae) gene (Jerse et al, 1990) and has an 83% amino acid 
homology between EPEC and EHEC strains (Yu and Kaper, 1992). The protein also 
has sequence homology with the invasin proteins in Yersinia pseudotuberculosis and 
Y. enterocolitica with the lowest homology at the N- and C-terminal ends (Jerse et al, 
1990; Yu and Kaper, 1992). The C-terminal end of intimin has been shown to bind to 
the surface of HEp-2 and HeLa cells (Frankel et al, 1994; Deibel et al, 2001) and it 
has been suggested the N-terminal end masks the C-terminus to prevent non-specific 
binding to host cells (Deibel et al, 2001). 
 Initmin is a membrane-bound protein that primarily targets Tir, which is 
translocated into host cells and expressed on their surface (Kenny et al, 1997a; 
Rosenshine et al, 1992; DeVinnney et al, 1999). Intimin is able to bind to the surface 
of epithelial cells independently of Tir by binding to host cell β1-integrins and the 
growth regulation protein nucleolin (Frankel et al, 1996; Sinclair and O’Brien, 
2004). Intimin binds Tir preferentially but it is possible that nucleolin acts as a target 
for adhesion before Tir is translocated into host cells (Sinclair and O’Brien, 2004).  
 
1.4.7 Translocated intimin receptor 
 
 As mentioned above, Tir is required for intimin binding to host cells and the 
formation of A/E lesions (Kenny et al, 1997a; Rosenshine et al, 1992; DeVinnney et 
al, 1999). It was independently described as EspE and is translocated into host cells 
via the T3SS (Deibel et al, 1998; Kenny et al, 1997a). In EPEC O127:H6, actin 
assembly requires phosphorylation of tyrosine 474 in Tir (Kenny, 1999), which 
results in the recruitment of the host cell proteins Nck, N-WASP and actin-related 
protein 2/ actin-related protein 3 (Arp2/3; Guenheid et al, 2001). The proteins CrkII 
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and Grb2 are recruited in EPEC infection but not in EHEC infection (Goosney et al, 
2001). 
 In EHEC O157:H7 and O55:H7 strains, the phosphorylation of Tir is not 
required because these strains lack tyrosine 474 (DeVinney et al, 1999; DeVinney et 
al, 2001). Instead these strains utilise a 12 amino acid motif containing an 
asparagine-proline-tyrosine sequence that recruits the proteins IRTKS, IRSp53, 
EspFU, N-WASP and Arp2/3 in a manner independent of Nck (Brady et al, 2007; 
Stevens and Frankel, 2014). The tyrosine in the amino acid motif can be 
phosphorylated in EPEC strains to initiate Nck-independent pedestal formation but at 
a much lower efficiency than in EHEC (Campellone and Leong, 2005). 
 
1.5 Differences in virulence factor expression by EPEC and EHEC 
 
 While most of the virulence factors mentioned above are produced by both 
EPEC and EHEC, each pathotype has unique virulence factors that differentiate 
them. 
 
1.5.1 Type IV bundle-forming pili 
 
 Bundle-forming pili (BFP) are produced by EPEC and are part of the Type 
IV pili family, which are expressed by several bacterial pathogens (Girón et al, 1991; 
Strom and Lory, 1993). They are encoded on an ~97kb EAF plasmid (Girón et al, 
1991; Nataro et al, 1987) by a cluster of 14 bfp genes, several of which are 
homologous to genes required for Type IV pilus production in other Gram-negative 
bacteria (Sohel et al, 1996; Stone et al, 1996). BfpA is the major subunit of BFP 
(Donnenberg et al, 1992) and is produced as a preprotein before being cleaved into a 
functional form by BfpP (Zhang et al, 1994). The proteins BfpD and BfpF bind 
nucleotides and act as ATPases to control pilin export and assembly (Sohel et al, 
1996; Stone et al, 1996). 
 BFP expression is controlled by the EAF plasmid-encoded regulatory 
proteins BfpT, V and W as well as the chromosome-encoded protein DsbA (Tobe et 
al, 1996; Zhang and Donnenberg, 1996). DsbA stabilises BFP by catalysing the 
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formation of disulphide bonds (Zhan and Donnenberg, 1996). Environmental signals 
also control BFP expression, with expression occurring optimally between 35°C and 
37°C during the exponential growth phase, in the presence of calcium (Puente et al, 
1996). Puente et al (1996) also found that ammonium suppresses the expression of 
BFP. 
 BFP are important virulence factors for the colonisation of hosts, including 
humans, by EPEC (Bieber et al, 1998) and are required for the formation of 
microcolonies and adhesion to epithelial cells (Girón et al, 1991). BFP bind to 
N-Acetyllactosamine on the surface of host enterocytes (Hyland et al, 2008) and also 
act in conjunction with E. coli common pili to form microcolonies (Saldaña et al, 
2009). They are important for initial adhesion of EPEC to host cells and are also 
involved in the dispersal of bacteria from microcolonies (Cleary et al, 2004; Knutton 
et al, 1999). 
 
1.5.2 Shiga toxin 
 
 The Stx family of cytotoxins is composed of two major groups, Stx1 and 
Stx2, which are produced in various combinations by EHEC (Nataro and Kaper, 
1998). Stx2, however, is more common in cases of haemorrhagic colitis and HUS 
(Croxen and Finlay, 2010). Stx1 is identical to Stx from Shigella dysenteriae 
serotype I and is highly conserved whereas Stx2 exhibits sequence variation and is 
separated into a series of subtypes (Nataro and Kaper, 1998). The stx genes are 
encoded by lysogenic lambdoid bacteriophages, which are integrated into the 
bacterial chromosome (O’Brien et al, 1984; Johansen et al, 2001) and Stx production 
is induced by activation of the phage lytic cycle (Nelly and Friedman, 1998). The 
regulation of Stx production is complex, with many different regulatory cues 
affecting gene expression including phage replication cycle, antibiotics, reactive 
oxygen species, iron concentration, temperature, growth phase and quorum sensing 
(Pacheco and Sperandio, 2012).  
 Stx is an AB5 toxin consisting of an A subunit, which in turn is made from an 
A1 and A2 peptide, that is non-covalently bound to a pentameric ring of B subunits 
(Stein et al, 1992; Fraser et al, 1994). The Stx toxins are not secreted but are released 
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as a result of phage-mediated lysis of the bacterial cell in response to DNA damage 
and the SOS response (Toshima et al, 2007), meaning that certain antibiotics can 
induce the phage lytic cycle and Stx production (Zhang et al, 2000). The B subunit 
pentamer binds to the Gb3 variant of the glycolipid receptor globotriaosylceramide 
that is present on the surface of Paneth cells in the intestine and kidney epithelial 
cells (Jacewicz et al, 1987; Lindberg et al, 1987). Stx2e, which is typically 
associated with porcine oedema disease, uses the Gb4 variant of this receptor (Pierard 
et al, 1991). Cattle lack the vascular Gb3 receptor meaning that EHEC infection in 
cattle is asymptomatic (Pruimboom-Brees et al, 2000). There is evidence to suggest 
that Gb3 can be found on crypt epithelial cells in cattle, however, Stx does not appear 
to be cytotoxic in these cells as it is localised in lysosomes (Hoey et al, 2003). 
 Once Stx binds to its receptor, it is endocytosed by both clathrin-dependent 
and independent mechanisms (Sandvig et al, 1989; Römer et al, 2007), and a 
protease sensitive loop connecting the A1 and A2 subunits is cleaved by the enzyme 
furin (Garred et al, 1995; Lea et al, 1999). The A subunits remain connected by a 
disulphide bond (Lea et al, 1999). Stx bypasses the late endocytic pathway to 
undergo retrograde transportation to the trans-Golgi network and then to the 
endoplasmic reticulum (ER; Sandvig et al, 1992; Mallerd et al, 1998). The remaining 
disulphide bond is reduced in the ER and the A1 subunit is translocated into the 
cytoplasm of the host cell (Johannes and Römer, 2010; Tam and Lingwood, 2007). 
Once in the cytoplasm, the A1 subunit exhibits N-glycosidase activity and removes 
an adenine nucleotide from the 28S rRNA of the host cell’s ribosomes, resulting in 
the inhibition of proteins synthesis and cell death (Endo et al, 1988). 
 Stx enters Gb3-negative intestinal cells via macropinocytosis (Malyukova et 
al, 2008) and is translocated through the cells into the bloodstream in order to reach 
the kidneys (Acheson et al, 1996). Stx is also capable of retrograde transportation in 
these cells but does not inhibit protein synthesis (Schüller et al, 2004). Instead it 






1.6 The discovery of lymphostatin 
 
 In 1995 Klapproth et al discovered that cell lysates of certain EPEC strains 
were capable of dose-dependent inhibition of cytokine expression by human 
peripheral blood mononuclear cells (PBMCs), but that lab strains, other E. coli 
pathotypes and whole bacteria lacked this ability. Lysates of EHEC O157:H7 strain 
EDL933 were found to inhibit cytokine expression but were not tested in a 
dose-dependent manner. Only one EPEC strain tested, O119:H6 0659-79, did not 
have inhibitory activity against PBMCs, which may be due to known variation in 
EPEC strains (Levine and Edelman, 1984). Klapproth et al (1995) were able to 
determine that inhibitory activity was caused by a protein or proteins encoded on the 
bacterial chromosome. They also found, using lysates of an E. coli lab strain 
transformed with an EPEC cosmid (pIV-8-A), that these lysates inhibited cytokine 
expression in human peripheral blood lymphocytes irrespective of the mechanism of 
lymphocyte activation. These cosmid clone lysates could also inhibit the 
mitogen-stimulated proliferation of lymphocytes. The inhibition observed in these 
experiments was not due to cellular toxicity. 
 In 1996, further experiments by Klapproth et al found that lysates of E. coli 
K-12 containing the EPEC pIV-8-A cosmid clone exhibited dose-dependent 
inhibition of interleukin-2 (IL-2) against lamina propria mononuclear cells (LPMCs). 
The inhibition of cytokine synthesis was non-selective and the inhibition of 
lymphocyte proliferation was not caused by the inhibition of IL-2 receptor 
expression. CD25 expression was not inhibited in CD45R0 cells by cosmid clone 
lysates. It was found that the inhibitory effect of EPEC O127:H6 strain E2348/69 
lysates was similar in mitogen-stimulated PBMCs and LPMCs. The culture 
supernatants of EPEC were also found to inhibit IL-2 and IL-5 expression in 
mitogen-stimulated PBMCs. Lastly, Klapproth et al (1996) found that EPEC and 
cosmid clone lysates could inhibit cytokine expression in lymphocytes activated by 
non-pathogenic E. coli bacterial products. 
 Malstrom and James (1998) observed that EPEC O127:H6 strain E2348/69 
lysates inhibited IL-2 expression in murine splenic cells stimulated with 12-myristate 
13-acetate and phytohaemagglutinin without causing apoptosis. EPEC lysates 
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inhibited multiple cytokines but increased the production of IL-10, which itself 
inhibits inflammatory cytokine expression. However, the inhibitory activity of EPEC 
lysates was independent of IL-10 and the regulatory cytokine TGF- β. Macrophages 
were also not required for the increased production of IL-10. IL-2 expression was 
inhibited by EPEC lysates in mitogen-stimulated Jurkat cells as well as small 
intestinal intraepithelial and Peyer’s patches lymphocytes. Pre-exposure of murine 
splenic cells to EPEC lysates resulted in decreased IL-2 and increased IL-10 
expression when the cells were both mitogen- and antigen-stimulated. Malstrom and 
James (1998) also found that lysates of EHEC O157:H7 strain ED933, RDEC-1 and 
C. rodentium had inhibitory activity against murine splenic lymphocytes and that this 
activity was not related to EspB, which was examined due its requirement for signal 
transduction in host cells and the activation of NF-κB transcription factors (Foubister 
et al, 1994; Savkovic et al, 1997) 
 In 2000 Klapproth et al discovered the protein responsible for the inhibitory 
activity, which they named lymphosatin or lymphocyte inhibitory factor A (LifA) 
due its ability to specifically inhibit lymphocyte proliferation and cytokine 
expression. DNA sequencing of the pIV-8-A cosmid determining inhibitory activity 
revealed the lifA gene to be 9,669bp encoding a predicted 365,950Da protein – the 
largest protein produced by E. coli. The deletion of the lifA gene from EPEC 
O127:H6 strain E2348/69 abolished the inhibitory activity of bacterial lysates but did 
not affect the A/E ability of intact cells. LifA homologues were found in non-O157 
EHEC, RDEC, and C. rodentium. Sequence homology was also found with proteins 
from Chlamydia trachomatis and the large clostridial toxin (LCT) family, including a 
predicted conserved N-terminal glycosyltransferase domain. However, unlike LCTs, 
EPEC lysates did not disrupt actin distribution in HEp-2 cells, suggesting that LifA 
does not function in the same manner as LCTs. 
  
1.7 Homologous proteins and sequences to lymphostatin 
 
 Nicholls et al (2000) discovered a protein in EHEC O111:H- strain E45035 
that increased the adhesion of bacteria to Chinese hamster ovary (CHO) cells in vitro 
and named it EHEC factor for adherence (Efa-1). Efa-1 was identical in size to LifA 
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and was predicted to be 99.9% identical to LifA at a nucleotide level and 97.4% 
identical at an amino acid level (Nicholls et al, 2000). As such, LifA and Efa-1 are 
thought of as the same protein and their names are used interchangeably in the 
literature. 
 LifA and homologous proteins have been found in EPEC, EHEC, RDEC, C. 
rodentium, H. alvei, and various Chlamydia species (Klapproth, 2010). EHEC 
O157:H7 does not produce LifA but rather encodes two homologous proteins. The 
first is LifA, which is a truncated version of LifA that is encoded on open reading 
frames z4332 and z4333 on O-island 122 of the chromosome (Hayashi et al, 2001; 
Perna et al, 2001). LifA is identical to amino acids 1 – 433 and 435 – 710 of LifA 
(Hayashi et al, 2001; Perna et al, 2001). It is unclear if only the 433 amino acid 
protein is made or if a 710 amino acid protein can be made via ribosome 
frameshifting. The second is ToxB, which is of a similar predicted size to LifA and is 
encoded on the EHEC O157:H7 large plasmid pO157 (Burland et al, 1998; Makino 
et al, 1998). ToxB is overall 47% homologous at the nucleotide level and 28% 
homologous at the amino acid level to LifA (Burland et al, 1998; Makino et al, 
1998). ToxB sequences have also been found in non-O157 EHEC strains and EPEC 
but the function of the encoded protein remains unclear (Badea et al, 2003; Tozzoli 
et al, 2005). In Chlamydia, C. psittaci contains a single lifA homologue, C. 
muridarum possesses three copies and C. trachomatis contains a pseudogene with 
frameshift mutations (Xie et al, 2003). Belland et al, 2001 have shown that these 
LifA homologues act as cytotoxins and suggested that it is possible that the 
immunomodulatory ability of LifA homologues may allow Chlamydia species to 
cause persistent infections. 
 
1.8 Secretion of lymphostatin 
 
 Little work has been carried out towards understanding the mechanism of 
secretion of LifA. Recently, Deng et al (2012) reported that LifA appeared to be 
secreted by the T3SS based on quantitative proteomic (SILAC) analysis of proteins 
secreted by EPEC O127:H6 strain E2348/69 in a T3SS-dependent manner. This 
involved mapping peptides across the protein and detecting them using mass 
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spectrometry. Reporter assays using the N-terminal 50 – 100 amino acids of LifA 
fused to TEM-1/β-lactamase showed that this sequence of LifA was capable of being 
injected into HeLa cells and reacting with a β-lactamase substrate to cause a colour 
change in fluorescence. Due to the limitations of the cloning vector that was used, 
the N-terminal 50 – 100 amino acids were used instead of the full-length protein. 
This was suitable for examining Type III secretion as Charpentier and Oswald (2004) 
found that as little as 20 amino acids from the N-terminus of various T3S proteins is 
sufficient to mediate translocation through the T3SS. However, without examining 
the full-length protein it is not possible to determine if Type III secretion is the 
normal mechanism of LifA secretion, or whether the protein is secreted in its entirety 
or in processed forms. It is possible that LifA may be secreted via different secretion 
systems. 
 The mechanism of LifA secretion is important for understanding how it acts 
as both a lymphostatin and an adhesin. Studies by Klapproth et al (1995, 1996 and 
2000), Malstrom and James (1998) and Stevens et al (2002) have all shown that 
bacterial lysates containing LifA have inhibitory activity against lymphocytes and 
mononuclear cells, indicating that injection is unlikely to be needed for lymphostatin 
activity. Moreover, activity can be transferred to laboratory-adapted E. coli K-12 
containing cloned LifA even though it lacks the T3SS. Purified recombinant LifA 
has also been found to inhibit the mitogen-stimulated proliferation of lymphocytes 
(Stevens Laboratory unpublished data). This suggests that even if LifA is Type III 
secreted, it does not absolutely require T3SS-mediated injection into host cells in 
order to function. 
 Exactly how LifA acts as an adhesin is unclear but there are multiple possible 
methods of how it may achieve this. It may gain access to host cells via the T3SS or 
other means, where like Tir, it becomes a receptor for another bacterial protein or 
recruits other proteins to act a receptor. An alternative method is that LifA is secreted 
and then re-associates with the bacterial cell surface before binding to a receptor. 
This mechanism has been observed with the giant fibronectin-binding adhesin SiiE 




1.9 Importance of lymphostatin as a virulence factor 
 
 LifA has been shown to be an important virulence factor in A/E pathogens 
(Stevens et al, 2002; Badea et al, 2003; Klapproth et al, 2005; Deacon et al, 2010). 
Stevens et al (2002) found that deleting the lifA gene in EHEC O5:H- strain S102-9 
caused a 19-fold reduction in adherence to HeLa cells. A reduction in adherence was 
not observed in the EPEC strain O127:H6 strain E2348/69 but this may have been 
due to the expression of BFP. Lysates of both EPEC O127:H6 strain E2348/69 and 
EHEC O5:H- strain S102-9 were found to inhibit the mitogen-stimulated 
proliferation of PBMCs, although the inhibition caused by EHEC may have been due 
to other toxins such as Stx. Stx is capable of inhibiting the proliferation of 
lymphocytes (Menge et al, 1999) and deleting the lifA gene did not relieve the 
inhibitory effect of the EHEC lysate. Deleting the lifA gene in EHEC O5:H- and 
O111:H- strain E45035N was found to reduce the adherence of bacteria to the 
intestinal epithelium of cattle, reduce the overall ability of the bacteria to colonise 
cattle and reduce pathology. It was also found that EHEC O5:H- ΔlifA mutants were 
reduced in their ability to produce and secrete EspA and Tir, but were still able to 
form A/E lesions. This suggests that the loss of LifA could have indirectly affected 
gut colonisation via indirect effects on Type III secretion, which is known to be vital 
for colonisation of the bovine gut by EHEC O157:H7 (Dziva et al, 2004; Naylor et 
al, 2005). 
 Badea et al (2003) reported that LifA was necessary for the in vitro 
adherence of rabbit EPEC to epithelial cells. The rabbit EPEC strain used lacked 
BFP, which would otherwise have likely masked the effects of LifA. Rabbit EPEC 
with mutated LifA had reduced adherence to CHO and HeLa cells and polyclonal 
antibodies against LifA also reduced adherence. The mutation of the lifA gene did 
not disrupt EspA secretion and therefore the decrease in adherence could not be 
attributed such a disruption. 
 Klapproth et al (2005) found that mutating the lifA gene in C. rodentium did 
not reduce the ability of the bacteria to colonise the colon of mice but did result in 
reduced pathology and accelerated clearance of the bacteria. In these experiments 
Klapproth et al (2005) mutated the putative glycosyltransferase and cysteine protease 
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domains as well as a domain between these two that does not encode any known 
activity. However, later it was discovered that the mutations created stop codons, 
which resulted in the truncation of the LifA protein (Deacon et al, 2010). This means 
that the results were invalid in relation to the effects of the specific domains but still 
proved that the protein as a whole is required for pathology in mice. 
 Deacon et al (2010) also investigated the importance of the putative 
glycosyltransferase and cysteine protease domains by substituting specific motifs 
within these domains in EHEC O26:H- strain 193 nalR. This strain was incapable of 
producing Stx1 in order to prevent it from masking the effects of LifA. It was found 
that LifA null mutants had a reduced ability to colonise cattle but mutants of the 
putative glycosyltransferase and cysteine protease domains did not. No effect of the 
lifA mutation on expression of EspA was observed in EHEC O26:H-. In contrast to 
Stevens et al (2002), this shows that LifA has a direct role in gut colonisation 
independently of EspA. LifA was not necessary to induce enteritis in bovine ileal 
loops. In contrast to previous experiments, LifA null and motif mutants did not have 
significantly reduced adherence to HeLa cells or ability to inhibit the 
mitogen-stimulated proliferation of lymphocytes. However, when the motif 
substitutions were transferred to the chromosome of EPEC O127:H6 E2348/69 it 
was observed that the ability to inhibit mitogen-stimulated proliferation of 
lymphocytes was significantly reduced in the motif mutants compared with parental 
EPEC E2348/69.  
 Stevens et al (2004) reported that the LifA homologues LifA and ToxB 
influenced the adherence of EHEC O157:H7 to HeLa cells but were not required for 
the colonisation of cattle or sheep. They also reported that mutations in the lifA and 
toxB genes reduced the production and secretion of proteins encoded by the LEE4 
operon but did not affect the activity of the LEE1, 4 and 5 operon promoters. This is 
consistent with observations by Tatsuno et al (2001) that suggest that ToxB affects 
expression and secretion of LEE-encoded proteins at a post-transcriptional level. 
Abu-Median et al (2006) also performed experiments with lifA and toxB mutants 
and found that these proteins did not appear to confer lymphostatin-like activity 
against mitogen-stimulated peripheral blood lymphocytes, however, the assay relied 
on crude bacterial lysates and is relatively insensitive. 
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1.10 Structural motifs of lymphostatin 
 
The N-terminal portion of LifA is ~40% homologous to the LCT family which 
includes TcdA and B from Clostridium difficile, the lethal and haemorrhagic toxins 
from C. sordellii and α-toxin from C. novyi (Klapproth et al, 2000; Nicholls et al, 
2000; Busch et al, 1998). This homologous region in LifA encompasses a catalytic 
DXD motif that is necessary for sugar binding in LCTs (Klapproth et al, 2000; 
Nicholls et al, 2000; Busch et al, 1998). The LCTs are known glycosyltransferases 
(Triadafilopoulos et al, 1987), most of which bind uridine diphosphate 
(UDP)-Glucose (Glc; Just et al, 1995; Schirmer and Aktories, 2004). C. novyi 
α-toxin can bind UDP-Glc but its primary substrate is UDP-N-Acetylglucosamine 
(GlcNAc; Selzer et al, 1996; Schrimer and Aktories, 2004). LCTs are known to act 
as cytotoxins by hydrolysing UDP-sugars and transferring the sugar onto Rho 
GTPases, thereby inhibiting RhoGTPase activity and causing the collapse of the 
actin cytoskeleton (Just et al, 1995; Selzer et al, 1996). Early experiments by 
Klapproth et al (1995 and 2000) and Stevens et al (2002) did not show LifA to act in 
this manner, however, recent experiments by Babbin et al (2009) suggest that LifA 
from C. rodentium targets Rho GTPases in mice. It is unknown whether this is true 
for LifA produced by EPEC and EHEC. Deacon et al (2010) were not able to 
replicate these results as they did not detect any activation of RhoA in cells infected 
with EPEC, and so the possible cytotoxic effects of LifA remain unclear. 
 LifA also contains a cysteine protease domain that is homologous to the 
YopT protein family in Yersinia (Shao et al, 2002). YopT proteins cleave Rho 
GTPases near their C-terminal end, releasing them from the host cell membrane and 
disrupting the actin cytoskeleton (Shao et al, 2002). The function of the cysteine 
protease domain in LifA is unknown. LCTs are autoproteolytic (Reinke et al, 2007), 
using this domain to release the catalytic N-terminal portion into the cytoplasm after 
insertion of the LCT across endosome membranes. It is therefore possible that if 
LifA acts in the same manner as LCTs, that the target of the cysteine protease 
domain is LifA itself. It appears that these glycosyltransferase and cysteine protease 
domains are dispensable during intestinal colonisation of calves by EHEC O26:H-, 
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however, they influence LifA activity, at least when assayed using crude bacterial 
lysates (Deacon et al, 2010). 
 
1.11 Recent advances in understanding the mode of action of lymphostatin 
 
 LifA clones are unstable and under-represented in cosmid libraries 
(Klapproth et al, 2000; Janka et al, 2002). Nicholls et al (2000) reported that they 
were unable to assemble the full-length lifA/efa-1 gene from cloned N- and 
C-terminal fragments and that the protein may be toxic to the E. coli cell. Recent 
work by the Stevens Laboratory has enabled the further study of LifA. Through the 
use of tightly inducible expression vectors, it has been possible to create a stable 
plasmid encoding recombinant LifA with a 6x-histidine (6xHis) tag. This 
recombinant LifA has been purified and biophysically characterised by our 
collaborators at the Edinburgh Protein Production Facility. It has been observed to 
bind UDP-GlcNAc but not UDP-Glc, suggesting it may act to some degree as a 
glycosyltransferase, and it is also capable of inhibiting the mitogen-stimulated 
proliferation of bovine T lymphocytes in a dose-dependent manner. Lastly, a rabbit 
polyclonal antibody has been produced against this recombinant LifA, allowing for 















1.12 Aims and objectives 
 
 Given that very little is understood about the molecular mechanisms of LifA 
activity, this study sought to determine a possible secretion mechanism for the 
full-length protein, to investigate the role of LifA as a putative glycoyltransferase 
and to examine the possible cytotoxic effects of LifA on mammalian cells. The 
overall objectives of this study were to: 
 
1. Determine if full-length LifA can be secreted via the T3SS by examining 
the secretion of LifA by EPEC wild-type (WT) and mutant strains under 
T3S-inducing conditions. 
 
2. Probe the role of a predicted DXD catalytic motif within the putative 
glycosyltransferase domain in LifA by: 
a) Creating a DXD-AAA substitution mutant and purifying the mutant 
protein. 
b) Comparing the sugar binding ability of the DXD-AAA mutant LifA 
protein with the WT protein. 
c) Comparing the ability of the DXD-AAA mutant LifA protein to 
inhibit the Concanavalin A (ConA)-stimulated proliferation of bovine 
T lymphocytes with the WT protein. 
 











Chapter 2: Materials and Methods 
 
2.1 Bacterial growth media and chemicals 
 
 Bacterial strains were cultured in suspension using lysogeny broth (LB) or on 
LB agar plates (Sigma Aldrich) and supplemented with antibiotics as indicated. 
Antibiotics were used at the following final concentrations: Nalidixic acid (Nal), 
20µg/mL; Kanamycin (Kan), 30µg/mL; Ampicillin (Amp), 25µg/mL. Where 
indicated, cultures were supplemented with 0.5% (w/v) D-glucose. Glycerol stocks 
for bacteria were prepared from fresh liquid cultures and supplemented with glycerol 
at a final concentration of 15% (v/v). For Type III secretion assays, bacteria were 
cultured in Eagle’s Minimum Essential Medium (Sigma Aldrich) supplemented with 
4-(2-hydroxyethyl)-1-piperazineethanesulphonic acid (MEM-HEPES, Sigma 
Aldrich), 1g/L D-glucose and antibiotics as indicated (MEM-C; Kenny et al, 1997b). 
 
2.2 Bacterial strains, plasmids and oligonucleotides 
 
 The strains and plasmids used in this study are listed in Table 2.1. The 
pRham-LifA-6xHis plasmid encodes the lifA gene, which is controlled by a 
rhamnose-inducible promoter. The pRham empty plasmid was a re-ligated pRham 
vector backbone and was used as a negative control. The oligonucleotides used for 











Table 2.1. Strains and plasmids used in this study. Properties of strains and 






E. coli E2348/69 WT EPEC O127:H6 strain. NalR 
Taylor, 1970; 
Levine et al, 
1978; 
Levine et al, 1985 
E. coli E2348/69 
ΔlifA 
Lacks lifA. NalR 
Stevens et al, 
2002 
E. coli E2348/69 
ΔescN::KanR 
Defective T3SS. KanR 
Garmendia et al, 
2004 
E. cloni® 10G  
Chemically competent cells for 
transformation. F¯mcrA 
Δ(mrr-hsdRMS-mcrBC) endA1 
recA1 Φ80dlacZΔM15 ΔlacX74 
araD139 Δ(ara,leu)7697 galU 
galK rpsL (StrR) nupG λ– tonA 




Chemically competent cells for 
transformation. TetR Δ(mcrA)183 
Δ(mcrCB-hsdSMR-mrr)173 
endA1 supE44 thi-1 recA1 gyrA96 
relA1 lac Hte [F´ proAB 










Encodes 6xHis tagged LifA with 
rhamnose inducible promoter. 
KanR 





Re-ligated pRham vector 
backbone. 
KanR 






Encodes 6xHis tagged LifA with 
rhamnose inducible promoter and 
DXD motif substituted with 
AAA. 
KanR Made in this study 
pWhitescript 






Transformation control. Allows 











Table 2.2. Oligonucleotides used in this study.  
 



































LifA FL For1 GCAGGAAAGATAGCTGGTAAC 
Sequencing of the 
DXD-AAA lifA gene 
from 5' to 3' 
Sigma 
Aldrich 
Lifa FL For2 GTTCCCCACCTGAAAGCATT As LifA FL For1 
Sigma 
Aldrich 
LifA FL For3 GGTGAAAACCGCATTTCAAT As LifA FL For1 
Sigma 
Aldrich 
LifA FL For4 CGTGGGCTCAATGGATTCATG As LifA FL For1 
Sigma 
Aldrich 
LifA FL For5 CCTGTTCAAAGATGTTTCAAC As LifA FL For1 
Sigma 
Aldrich 
LifA FL For6 GACTCCTGAAAACTGGGAAG As LifA FL For1 
Sigma 
Aldrich 
LifA FL For7 CGGACTAGGAATAACTGGTG As LifA FL For1 
Sigma 
Aldrich 
LifA FL For8 GGATTACCAACTATTGCCG As LifA FL For1 
Sigma 
Aldrich 
LifA FL For9 CCAACGAATCGCTACTACA As LifA FL For1 
Sigma 
Aldrich 
LifA FL For10 CTGTCCCGCACAGTTCTGAC As LifA FL For1 
Sigma 
Aldrich 
LifA FL For11 CCGAAGCAACTCTCGGCAGC As LifA FL For1 
Sigma 
Aldrich 
LifA FL For12 CAGTCTCCTCCTCTCTTGC As LifA FL For1 
Sigma 
Aldrich 
LifA FL For13 CCGGAAGAGTTTCCGCTCACC As LifA FL For1 
Sigma 
Aldrich 
LifA FL For14 CAGGCTGTTTATCCGGAAG As LifA FL For1 
Sigma 
Aldrich 
LifA FL For15 GGTCATACACCAACGGTAAAC As LifA FL For1 
Sigma 
Aldrich 
LifA FL For16 GAACAGCCAGGTATCGGCAG As LifA FL For1 
Sigma 
Aldrich 






2.3 Culture of mammalian cell lines 
 
 HeLa cells were cultured at 37ºC, 5% CO2 in Dulbecco’s Modified Eagle’s 
Medium (DMEM, Gibco and Sigma Aldrich) with 10% (v/v) heat-inactivated foetal 
calf serum (FCS, Gibco) and 20mM L-glutamine (Gibco; DMEM-C). The cells were 
grown to a confluence of 80 – 90% then passaged into fresh medium as follows. The 
cell monolayer was washed with 10mL Hank’s balanced salt solution (HBSS, Gibco) 
and cells lifted by incubation with 2mL trypsin (1x; 0.05% (w/v) trypsin; 0.02% 
(w/v) EDTA in HBSS, Sigma Aldrich) at 37ºC for ~2 – 3 minutes. The cells were 
dislodged from the flask by rinsing with 10 volumes (V) DMEM-C. The cells were 
then centrifuged at 1200g for 10 minutes at room temperature. The cells were 
resuspended in fresh medium, counted by trypan blue exclusion (0.4% (w/v) trypan 
blue, HyClone) using disposable haemocytometer grids (Kova International) and 
re-seeded at a density of 0.5x106 cells/mL in a T175 filter cap flask (Fisher 
Scientific). TIB-152 (Jurkat) cells were cultured in suspension at 37ºC, 5% CO2 in 
RPMI-1640 medium (Gibco) with 10% (v/v) FCS (Gibco) and 20mM L-glutamine 
(Gibco; RPMI-CJ) to a density of 3x106 – 7x106 cells/mL. The cells were centrifuged 
as above and the pellet was resuspended in fresh RPMI. Jurkat cells were counted as 
above and re-seeded at a density of 0.5x106 cells/mL. For long-term storage at 
-150ºC, cells were spun down and resuspended in RecoveryTM Cell Culture Freezing 
Medium (10% (v/v) DMEM with 10% (w/v) dimethylsulphoxide, Invitrogen) at a 
density of 1x106 cells/mL, frozen in a cell freezer at -80ºC overnight, followed by 




Primer (cont.) Sequence (5' to 3') Purpose Source 
LifA FL For18 GCGGCTACCAAGTGTATTATC As LifA FL For1 
Sigma 
Aldrich 
LifA FL Rev15 CCATCAGATATTGCACGACG 
Sequencing of the 
DXD-AAA lifA gene 
from 3' to 5' 
Sigma 
Aldrich 




2.4 Plasmid DNA purification 
 
 Plasmid DNA was prepared from small-scale stationary phase bacterial 
cultures (5 – 10mL, Miniprep) or larger-scale cultures (50 – 100mL, Midiprep). To 
perform a Miniprep, 3mL from overnight cultures were each added to two 1.5mL 
microcentrifuge tubes and centrifuged at 17,949g for 10 minutes. DNA from the 
pellets was purified using a QIAprep Spin Miniprep Kit (Qiagen) following the 
manufacturer’s instructions. One QIAprep spin column was used for each 3mL 
culture and columns were left to dry for 10 minutes. The DNA was eluted in 30µL of 
nuclease free distilled water (nH2O), which was left to stand for 5 minutes before 
being centrifuged for 1 minute. 
 To perform a Midiprep, 50mL overnight cultures were centrifuged at 6000g, 
4°C for 15 minutes. Plasmid DNA from the pellets was purified using a QIAprep 
Spin Midiprep Kit with filter cartridges (Qiagen) following the manufacturer’s 
instructions and the final DNA pellet was dissolved in 50µL of nH2O.  
The DNA concentrations were measured in ng/µL using a NanoDrop 
(ND-1000) Spectrophotometer (Thermo Scientific). 
 
2.5 Preparation of secreted proteins 
 
 Duplicate mid-logarithmic phase cultures of the EPEC E2348/69 (WT), 
E2348/69 ΔlifA (ΔlifA) and E2348/69 ΔescN::KanR (ΔescN) strains were grown from 
1.5mL of overnight LB cultures in 25mL of MEM with appropriate antibiotics. They 
were incubated at 37ºC for 5 hours so that the OD600 of the cultures was between 0.3 
and 0.6. Each set of cultures was pooled and 100µL was taken from each to 
enumerate viable bacteria by plating of serial dilutions onto LB agar plates with 
appropriate antibiotics with incubation at 37ºC overnight. The number of colonies on 
plates with 30 – 300 colonies were counted and multiplied by the dilution factor, and 
this value was divided by the volume plated in mL to give the number of colony 
forming units (CFUs). 
 The pooled cultures were centrifuged at 3220g, 4ºC for 10 minutes, before 
the supernatants were decanted and filtered through a 0.2µm filter (Ministart 
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Sartorius) to remove any residual bacteria. Proteins were precipitated by the addition 
of trichloroacetic acid (Sigma Aldrich) to a final concentration of 10% (v/v) with 
incubation at 4ºC overnight. The samples were centrifuged at 3220g, 4ºC for 1 hour, 
the supernatant was decanted, and the pellets were left to air dry before being 
resuspended in 200µL of 1.5M Tris(hydroxymethyl)aminomethane (TRIS) buffer 
(pH 8.8). Protein samples were denatured by the addition of an appropriate volume 
of sample reducing agent (Novex) and 1x lithium dodecyl sulphate (LDS) sample 
buffer (Novex) and heated at 70ºC for 10 minutes. Samples were stored at -20ºC 
until analysis. 
 The bacterial pellets were resuspended in 50mL of phosphate-buffered saline 
(PBS) and 1mL was processed to make whole cell lysates. The samples were washed 
by centrifugation at 17,949g, 4ºC for 10 minutes, washed in PBS and centrifuged 
again. The pellets were lysed using 100µL of BugBuster MasterMix (Novagen) and 
mixed for 10 minutes at room temperature. Protein concentration was quantified 
using the Direct Detect system (Merck Millipore) according to the manufacturer’s 
instructions using BugBuster as the buffer control. The samples were then denatured 
in sample reducing agent and LDS sample buffer as above. Samples were stored at 
-20ºC until analysis. 
 
2.6 Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) 
 
 Proteins were analysed by SDS-PAGE using the Novex (Life Technologies) 
gel system. Where the detection of LifA was required, 3 – 8% Tris-Acetate gels 
(Novex) were used. For analysis of proteins <100kDa, 4 – 12% Tris-Glycine gels 
(Novex) were used. The Tris-Acetate and Tris-Glycine gels were run with 1x 
Tris-Acetate SDS running buffer (Novex), with 0.25% (v/v) antioxidant (Invitrogen) 
in the buffer that was in contact with the anode of the gel tank, and 1x Tris-Glycine 
SDS running buffer (Novex) respectively. HiMark pre-stained protein standards 
(Invitrogen) and Precision Plus Protein pre-stained standards (Bio-Rad) were used 
with the Tris-Acetate and Tris-Glycine gels respectively. The gels were run at 150V 
until the dye front had left the bottom of the gel. Gels were analysed by staining with 
Coomassie stain (Bio-Rad), according to the manufacturer’s instructions, or by 
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western blot detection. Where the gels were stained, the images were captured using 
a Gel Doc EZ system (Bio-Rad). 
 
2.7 Western blotting 
 
 Proteins were transferred to polyvinylidene fluoride (PVDF) membranes 
(Amersham Hybond) for western blotting. The gels were soaked in 2x transfer buffer 
(Novex) with 0.04% (w/v) SDS for 15 minutes while PVDF membranes were 
washed in methanol then distilled water before being soaked and gently rocked in 2x 
transfer buffer with 10% (v/v) methanol and 0.1% (v/v) antioxidant for 15 minutes. 
To get efficient transfer of large proteins (>100kDa), the Tris-Acetate gels were 
transferred using a wet transfer at 30V for 75 minutes, using an XCell II Blot Module 
(Thermo Scientific). The Tris-Glycine gels were transferred using the semi-dry 
method at 15V for 60 minutes in a Trans-Blot Turbo Transfer System (Bio-Rad). 
Membranes were blocked in Tris-buffered saline/0.1% (v/v) Tween 20 (TBS-T, 
VWR International) and 5% (w/v) bovine serum albumin (BSA, Merck Millipore) 
for 1 hour on a rocker, then rinsed briefly with TBS-T and washed for 15 minutes, 
followed by an additional two washes of 5 minutes. Each membrane was treated with 
either rabbit polyclonal anti-LifA (Stevens Laboratory, Clone 45), mouse 
monoclonal anti-RecA (LifeSpan Biosciences) or mouse monoclonal anti-EspD 
(Ebel et al, 1998) antibody at dilutions of 1/25,000, 1/10,000 and 1/5000 respectively 
in TBS-T/5% (w/v) skimmed milk powder (Chem Cruz). All of the membranes were 
incubated at 4ºC overnight. 
 Blots were washed with TBS-T as above. Horseradish peroxidase 
(HRP)-conjugated secondary antibodies were applied at the following concentrations 
in TBS-T/2% (w/v) skimmed milk powder: goat anti-rabbit HRP (Bio-Rad), 
1/10,000; goat anti-mouse HRP (AbD Serotec), 1/10,000. The membranes were 
incubated at room temperature for 1 hour and the blots washed TBS-T as above. The 
membranes were dried and developed using SuperSignal West Pico 
Chemiluminescent Substrate (Thermo Scientific) following the manufacturer’s 
instructions and exposed to Amersham Hyperfilm for various times to achieve clear 
images. Films were developed using an SRX-101A film processor (Konica Minolta). 
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2.8 Site-directed mutagenesis of the DXD motif of lymphostatin 
 
 Mutagenesis of the DXD motif was performed using a QuikChange II XL 
Site-Directed Mutagenesis Kit (Figure 2.1, Agilent Technologies) following the 
manufacturer’s instructions with some modifications. The primers LifA-DXD-1 
(forward) and LifA-DXD-2 (reverse; see Table 2.2) were designed using the 
QuikChange Primer Design Program (www.agilent.com/genomics/qcpd), with the 
aim of replacing DXD at amino acid positions 557 – 559 of E2348/69 lifA with 3 
alanine residues using codons that simultaneously create a Not I restriction site. 
Polymerase chain reaction (PCR) was performed using 10ng of the 
pRham-LifA-6xHis plasmid as a template, 1x reaction buffer, 125ng of each of the 
forward and reverse primers, 2% (v/v) dNTP mix, 6% (v/v) QuikSolution reagent 
and nH2O to make up to 50µl reaction volume. PfuUltra HF DNA polymerase was 
added to the reaction mixture at 2.5U/µL. PCR was used to introduce the AAA 
sequence by complete replication of the plasmid, followed by digestion of the parent 
plasmid using 10U/µL Dpn I, which digests methylated template DNA but not DNA 
generated in the PCR reaction. A commercial pWhitescript plasmid was used as a 
positive mutagenesis control, using primers (sequence not disclosed by 
manufacturer) that repair a mutation in the β-galactosidase gene, which can be 
detected by blue-white screening using a chromogenic β-galactosidase substrate. The 
PCR parameters are listed in Table 2.3. 
 XL 10-Gold Ultracompetent cells were thawed on ice and prepared according 
to the manufacturer’s instructions. The Dpn I-treated DNA samples were added to 
separate aliquots of cells. A quantity of 0.01ng of pUC18 plasmid was added to an 
aliquot of cells for use as a transformation control. The transformation reactions were 
gently swirled and incubated on ice for 30 minutes. The cells were transformed by 
heat shock at 42ºC for 30 seconds and incubated on ice for 2 minutes. The cells were 
suspended in NZY+ broth (see Appendix 1), which was used as a recovery medium 
before plating, and incubated at 37ºC for 1 hour with shaking at 225 – 250rpm. The 
cells transformed with the mutant plasmid were spread onto LB/Kan agar with 0.5% 
(w/v) glucose and cells transformed with the pWhitescript and pUC18 plasmids were 
spread onto LB/Amp agar. The LB/Amp plates also had 250µL of 80µg/mL X-gal 
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(Promega) and 250µL of 20mM IPTG (Sigma Aldrich) spread onto the agar before 
the cells were added to allow for blue-white screening. The plates were incubated at 
37°C for >16 hours. 
 
Table 2.3. PCR programme used for site-directed mutagenesis of the 
pRham-LifA-6xHis plasmid. 
 
Segment No. of cycles Temperature (°C) Time 
1 1 95 1 minute 
    95 50 seconds 
2 18 68 50 seconds 
    68 13 minutes (1 minute/kb of plasmid) 
3 1 68 7 minutes 




















































Figure 2.1. The process of creating the DXD-AAA substitution mutant of LifA. 
(A) Nucleotide and amino acid sequence of the part of the catalytic DXD motif 
within the putative glycosyltransferase domain of LifA, highlighting the codons that 
were targeted for site-directed mutagenesis in order to create an AAA substitution 
mutant. It was also possible to incorporate a new Not I restriction site (GCGGCCGC) 
at this location. (B) Schematic of the procedure for QuikChange Mutagenesis. 
Mutant strand synthesis is carried out using the mutagenic primers to replicate the 
entire plasmid using PCR. This is followed by Dpn I digestion of methylated and 
hemimethylated template DNA to remove the parental plasmid DNA. Finally, the 
mutated plasmid is transformed into chemically competent cells (adapted from 






2.8.1 PCR screening of putative mutant constructs 
 
 Putative clones of pRham-LifA-6xHis with the DXD-AAA change were 
initially screened by PCR to verify that they contained plasmid harbouring the lifA 
gene. Glycerol stocks were made from each of the cultures, which were stored at 
-80°C for further use and 2µL of each culture was lysed in 198µL of nH2O. The 
lysed cells were mixed with 1x PCR master mix, which contained 1x HF buffer 
(Thermo Scientific), 10µM pRham forward primer, 10µM pETite reverse primer (see 
Table 2.2), 10mM dNTPs and 2U/µL Phusion polymerase (Thermo Scientific) to 
make up 20µL reaction volume. A no-template negative control and a parent plasmid 
DNA pRham-LifA-6xHis positive control were included. The PCR parameters are 
listed in Table 2.4. The PCR products were analysed on a 0.8% (w/v) agarose 
(Invitrogen) gel against a 1kb DNA ladder (Promega). Gels stained with SYBRsafe 
(Invitrogen) were run at 120V for 20 minutes. 
 
Table 2.4. PCR programme used for screening transformants. 
 
Segment No. of cycles Temperature (°C) Time 
1 1 98 10 seconds 
    98 10 seconds 
2 25 55 15 seconds 
    72 10 minutes 
3 1 72 10 minutes 
4 1 4 ∞ 
 
2.8.2 Not I digests of plasmids 
 
Not I was used to distinguish between mutated lifA, which contains a Not I 
restriction site at the location of the DXD-AAA substitution (see Figure 2.1), and 
false positives. Miniprep DNA from the colonies that tested positive for the presence 
of lifA were mixed with 1x Not I master mix, which contained 1x buffer D, 10mg/mL 
BSA, 10U/µL Not I (all from Promega) and nH2O. A negative and positive control of 
nH2O and pRham-LifA-6xHis plasmid were also treated with Not I. The DNA was 
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digested at 37°C for 1 hour and the digestion products were analysed on a 0.8% 
(w/v) agarose gel against a 1kb DNA ladder. Gels were run as previously described. 
 
2.8.3 Sanger sequencing of mutated plasmids 
 
Mutant plasmids were verified by conventional Sanger sequencing by GATC 
Biotech. The LifA forward primers FL For1 – 18, the reverse primers FL Rev15 and 
16 and the pRham forward primer (see Table 2.2) were used to sequence the entire 
lifA gene. 
The sequences were assembled using Lasergene SeqMan Pro (DNASTAR). 
Briefly, the sequence was clipped using SeqMan Pro to remove any areas of low 
sequence quality. The complete sequence was constructed by creating a contig of 
overlapping sequences in SeqMan Pro and differences in the original sequences were 
resolved by comparison of overlapping sequences with reference to sequencing 
chromatograms if needed. The complete sequence was compared with the WT E. coli 
E2348/69 genome using NCBI Blast (Iguchi, 2009; Madden, 2003) to identify any 
undesirable mutations that may have been introduced to the sequence (see Appendix 
2). 
 
2.9 Pilot protein expression assays 
 
Protein was overexpressed in E. cloni® 10G and XL 10-Gold Ultracompetent 
cells transformed with the pRham-LifA-6xHis and pRham-LifA-6xHis DXD-AAA 
plasmids respectively. E. cloni® 10G with the pRham empty plasmid was used as a 
negative control. Fresh 50mL LB subcultures were made from overnight cultures 
inoculated with single colonies. The subcultures were incubated at 30°C until they 
reached an OD600 between 0.5 and 0.6. Uninduced samples were collected and 0.2% 
(w/v) L-rhamnose was added to induce LifA production. At 2 hours post-induction, 
the induced and uninduced samples were centrifuged at 3220g, 4°C for 20 minutes 
and the pellets were collected, washed in PBS and centrifuged again. Protease 
inhibitors (Roche) were added to the cell suspension, which was then lysed by cell 
disruption (20kpsi, Constant Cell Disruption Systems). The lysates were centrifuged 
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at 3220g, 4°C for 20 minutes, the supernatant was decanted, and pellets were further 
lysed in 1mL BugBuster for analysis by SDS-PAGE. 
Protein concentrations of the soluble lysates were measured and the samples 
were denatured as previously described. The samples were centrifuged at 17,949g for 
10 minutes to separate the large cell debris and analyzed by western blotting as 
described above. 
 
2.10 Optimisation of DXD-AAA LifA protein production  
 
Overnight cultures of E. cloni® 10G transformed with the pRham-LifA-6xHis 
DXD-AAA plasmid, grown in LB/Kan broth were diluted 10-fold in Enpresso B 
media (BioSilta) and grown at 37°C to an OD600 of 0.5. Cultures were cooled to the 
appropriate induction temperature and induced with the addition of 0.2% (w/v) 
L-rhamnose when the OD600 reached 0.6. The cultures were incubated at either 20 or 
30°C and OD600 measurements were taken 30 minutes, 1, 2, 3 and 4 hours after 
induction. Aliquots of 1mL of culture were taken at each time point. The aliquots 
were centrifuged at 12,500g in a benchtop centrifuge for 10 minutes, the supernatant 
was discarded and the pellets were stored at -20°C until ready for further processing. 
The pellets were dissolved in 6µL of BugBuster for every 0.01 OD600 unit measured 
and sonicated with 3 x 10 second bursts using a Soniprep 150 Ultrasonic 
disintegrator (MSE). The pellets were kept on ice in between sonication bursts. A 
volume of 5µL from each lysate was mixed with 5µL of 10x sample reducing agent 
and 5µL of 4x LDS sample buffer then boiled at 100°C for 2 minutes and run on a 
4 – 12% Tris-Glycine gel (Bio-Rad) at 250V for 22 minutes. 
Large-scale protein production was carried out by first inoculating 2 x 25mL 
LB/Kan overnight cultures with a single colony each. From these overnight cultures, 
5mL was added to each of 10 x 500mL LB and grown at 30°C for 3 hours with 0.2% 
(w/v) L-rhamnose. The cultures were centrifuged at 6000g, 4°C for 20 minutes, the 
supernatant was discarded, and the pellets were flash frozen in liquid nitrogen and 




2.11 Purification of DXD-AAA LifA 
 
The DXD-AAA LifA protein was purified using a five-step process using ion 
metal affinity chromatography (IMAC), size exclusion chromatography (SEC), ion 
exchange chromatography and two desalt columns on a fast protein liquid 
chromatography (FPLC) unit (ÄKTA Explorer 10 UV900 LC system, GE Healthcare 
Life Sciences ÄKTA). All buffers used throughout the purification process were 
filtered and degassed to remove particulate matter (see Appendix 1 for their 
compositions). The presence of the DXD-AAA LifA protein in the filtrates 
throughout the purification was monitored using SDS-PAGE and UV absorbance at 
280nm. The operation of the FPLC unit was carried out by Dr Liz Blackburn 
throughout the purification process at The Edinburgh Protein Production Facility. 
Initially, the protein lysate was subjected to HiTrap nickel-Sepharose IMAC 
column chromatography (GE Healthcare Life Sciences). Cell pellets were thawed, 
lysed with IMAC lysis buffer (IMAC buffer A (see Appendix 1) with 500mM 
non-detergent sulphobetaine 201, 1 protease inhibitor tablet/1L of cell culture, 
0.1mg/mL benzamidine and 0.1% (v/v) phenylmethanesulphonylfluoride to prevent 
protein degradation) and lysed further by cell disruption (30kpsi, Constant Cell 
Disruption Systems). The lysed pellet lysate was centrifuged at 50,000g, 4°C for 1 
hour then run over the column at a flow rate of 2mL/minute, followed by a wash of 
22 column volumes (CV) of 4% IMAC buffer B (see Appendix 1), equivalent to 
20mM imidazole. The DXD-AAA LifA protein was eluted with 3 CV of 100% 
IMAC buffer B containing 500mM imidazole and collected in 1mL fractions. 
The fractions of the IMAC filtrate that contained DXD-AAA LifA were 
pooled and applied to a Superose-6pg XK16/60 SEC column (GE Healthcare Life 
Sciences), for size exclusion, using SEC buffer. The most pure IMAC fractions, 
determined by SDS-PAGE, were run through the column first, followed by the less 
pure fractions. 
The fractions of the SEC filtrates that contained DXD-AAA LifA, 
determined by SDS-PAGE, were run through a HiPrep 26/10 desalt column (GE 
Healthcare Life Sciences) in a 50mM NaCl low salt buffer to remove excess salt that 
may interfere with binding to the ion exchange chromatography column. 
 40 
The desalt fractions containing DXD-AAA LifA, determined by SDS-PAGE, 
were applied to a Mono Q strong anion exchange column (GE Healthcare Life 
Sciences) to separate proteins based on their net charge. The percentage of 1M NaCl 
buffer in the column was increased gradually from 0% to 50%, then sharply to 100%. 
The fractions of the ion exchange filtrates that contained LifA were then run through 
another desalt column to remove excess salt. The most pure fractions were pooled 
into a single aliquot, which was used in all further experiments involving DXD-AAA 
LifA. Protein concentration was quantified using a NanoDrop Lite 
Spectrophotometer (Thermo Scientific). Two batches of DXD-AAA LifA were 
desalted into either assay buffer or CD buffer (see Appendix 1) before use in the 
biophysical charaterisation and sugar binding experiments. 
 
2.12 Dynamic light scattering (DLS) 
 
Assay buffer with 1.1µM DXD-AAA LifA was passed through a 0.22µm 
Ultrafree-MC filter (Merck Millipore) and centrifuged at 12,000g, 4°C for 15 
minutes. The mean hydrodynamic radius of DXD-AAA LifA was measured using a 
Zetasizer Automated Plate Sampler (Malvern Instruments, UK) equipped with a 
50mW laser light source, with a wavelength of 830nm. DLS data were collected at a 
scattering angle of 90° for 10 seconds. This was repeated 12 times in triplicate and 
the values were averaged. Autocorrelation data were fit to a model of a 
multiple-exponential form suitable for polydisperse solutions using the 
protein-specific software supplied with the instrument. This generated a distribution 
of particles by size (Maslon et al, 2010). Assay buffer was used as a background 
control. Experimental data collection and analysis was carried out by Liz Blackburn, 
observed and supported by the candidate. 
 
2.13 Circular dichroism (CD) 
 
Samples of 0.11µM WT and DXD-AAA LifA in CD buffer were centrifuged 
at 12,000g, 4°C for 15 minutes. The samples were first checked for aggregation in 
CD buffer by DLS as described above. The mean residue ellipticity ([θ]) for each 
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protein was measured using a J-810 Spectropolarimeter (Jasco; Kelly et al, 2005) 
between wavelengths of 190 and 260nm. The [θ] for each protein was plotted against 
wavelength using Microsoft Excel 2013. The percentage of different secondary 
structure motifs were determined using DichroWeb 
(http://dichroweb.cryst.bbk.ac.uk/html/home.shtml; Lobley et al, 2002). 
Experimental data collection and analysis was carried out by Liz Blackburn. 
 
2.14 Thermal shift assays 
 
WT and DXD-AAA LifA proteins at a concentration of 0.1µM in assay 
buffer, along with a buffer control were mixed with 5x SYPRO orange and put into a 
96 well plate. The plate was sealed and centrifuged at 3220g for 2 minutes to remove 
air bubbles then put into an IQ5 Multicolor Real-Time PCR Detection System 
(Bio-Rad). The temperature was increased from 15 to 70°C in 0.5°C increments 
every 30 seconds and the fluorescence was recorded at each increment. A second 
thermal shift assay was performed with the addition 0.2µM DXD-AAA LifA to 
determine whether the concentration of protein would affect the unfolding 
temperature of the protein. Normalised relative fluorescence units (RFU) for each 
sample were plotted against temperature using Microsoft Excel 2013. The unfolding 
transition temperature (Tm) of each protein was calculated from the steepest part of 
the melting curve. To find the steepest part of the melting curve, the curves were 
differentiated with respect to temperature (T; -dRFU/dT), therefore the Tm of each 
protein was the average of the lowest -dRFU/dT values. 
 
2.15 Determination of sugar-binding ability of WT and DXD-AAA LifA 
 
Samples were excited at 295nm and fluorescent emission was collected from 
310 to 400nm in 1nm increments every second. The temperature of all samples was 
held at 20°C in the temperature controlled cuvette holder of the spectrophotometer 
(Fluoromax 3 Spectrophotometer, HORIBA Jobin Yvon). Assay buffer was put in a 
quartz cuvette to measure the background fluorescence. Protein was added at a 
concentration of 0.05µM and the fluorescence was measured again. Titrations of 
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increasing UDP-sugar concentrations were carried out, the fluorescence of each 
titration point was measured and background fluorescence subtracted. The 
fluorescence of the solutions was recorded in triplicate and the values were averaged. 
UDP-sugar was added between each triplicate of scans. UDP-GlcNAc and UDP-Glc 
(both Sigma Aldrich; both >98% pure) were titrated against buffer as a negative 
control. The experiment in which UDP-GlcNAc was titrated against WT LifA was 
performed by Liz Blackburn while all others were performed by myself. The results 
were analysed by Liz Blackburn using the law of mass action and the Stern-Volmer 
relationship. 
 
2.16 Preparation of bovine lymphocytes and T cell enrichment 
 
Peripheral blood was collected into heparinised bags from 3 different 12 – 18 
month old Holstein-Friesian calves. Blood was centrifuged at 1200g for 15 minutes 
with no brake and the lymphocyte interfaces were removed, pooled into two 
centrifuge tubes, and made up to 30mL with PBS. Each 30mL was overlaid onto 
20mL Ficoll-Paque Plus density medium (GE Healthcare Life Sciences) and 
centrifuged at 1200g for 25 minutes with no brake. The lymphocyte cells at the 
interface were removed and pooled for each donor and made up to 50mL with PBS 
and centrifuged at 1200g for 10 minutes. Where the cells were contaminated with 
erythrocytes, the pellet was resuspended in 1mL of red blood cell lysis buffer (see 
Appendix 1) and then made up to 50mL with RPMI-1640 medium (Gibco) with 10% 
(v/v) FCS (Gibco), 20mM HEPES (Sigma Aldrich), 1mM sodium pyruvate (Gibco), 
20mM L-glutamine (Gibco) and 100µg/mL penicillin/streptomycin (Sigma Aldrich; 
RPMI-CT). The cells were washed twice in RPMI-CT and resuspended in 2mL 
RPMI-CT. The cells were then counted as described above. 
To enrich for T cells, a nylon wool fiber column (Polyscience Inc.) was 
conditioned by adding 10mL RPMI-CT, tapping to remove air bubbles, and draining 
the media. The column was washed twice with RPMI-CT, filled with 5mL 
RPMI-CT, sealed and incubated at 37°C, 5% CO2 for 1 hour. The media was drained 
from the column, cells were applied at a density of 1x108 cells/mL and run into the 
column. The column was sealed and incubated at 37°C, 5% CO2 for 1 hour. The cells 
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were eluted from the column, which was then washed twice with RPMI-CT to 
remove any cells residual cells. The cells were counted as described above and the 
concentration was adjusted to be 4x106 cells/mL. 
 
2.16.1 T lymphocyte proliferation assays 
 
Wells of a 96 well plate were seeded in triplicate with 2x105 cells in 50µL 
RPMI-C. Serial dilutions were made for the WT and DXD-AAA LifA at 
concentrations of 400 – 0.004ng/mL and 40µg/mL – 0.4ng/mL respectively. The 
buffer that the mutant protein was dissolved in (see Appendix 1) was diluted using 
the same volumes as the DXD-AAA LifA dilution series as a control. Titrations of 
protein and buffer were added in triplicate to the appropriate wells at the following 
concentrations in 25µL: WT LifA, 100 – 0.001ng/mL; DXD-AAA LifA,  
10µg/mL – 0.1ng/mL; dilutions of buffer representing 10µg/mL, 100ng/mL and 
0.1ng/mL of mutant LifA. Concanavalin A (ConA) at a concentration of 50µg/mL 
was added to the cells in a volume of 25µL RPMI-CT. A background control was set 
up using 100µL RPMI-CT. Cells alone and cells with ConA, made up to 100µL with 
RPMI-CT, were used as negative and positive controls respectively. Empty wells 
were filled with PBS to prevent evaporation of the media. 
The plates were incubated at 37°C, 5% CO2 for 3 days and at 16 hours before 
the end of the assay 20µL CellTitre 96 AQueous One Solution (Promega) was added to 
each well. The absorbance was read at 492nm using a Multiskan Ascent 
Spectrophotometer (Thermo Scientific). Ratios of the absorbance value for each 
titration against the positive control were calculated using averaged experimental 
(E), maximum proliferation (Mp) and background (B) absorbance values with the 
following formula: 
 
Ratio of cells+LifA/cells+ConA alone = (E – B)/(Mp – B) 
 
The ratios were plotted against the concentration of WT or DXD-AAA LifA 
protein added with standard deviations using Microsoft Excel 2013. The ED50 for the 
WT and DXD-AAA LifA was calculated using R with the drc package (R Core 
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Team, 2015). The standard error of the mean was calculated for each ED50 using 
Minitab 17. 
 
2.17 Cytotoxicity assays 
 
HeLa and Jurkat cells were seeded in triplicate at a density of 
25x103 cells/50µL in opaque sided 96 well plates (Costar). Cells alone were used as a 
positive control. Media alone and buffer only were included as background and 
negative controls respectively. WT LifA titrations of 10µg/mL – 1ng/mL were 
applied in 50µL DMEM-C or RPMI-CJ to the appropriate cells, which were 
incubated at 37°C, 5% CO2. Two identical plates were set up for each assay and one 
was incubated for 24 hours and the other for 48 hours. Empty wells were filled with 
PBS to prevent evaporation of the media. 
 At 24 and 48 hours, a cytotoxicity assay was performed on the cells using a 
CytoTox-ONE Homogeneous Membrane Integrity Assay Kit (Promega) following 
the manufacturer’s instructions. The cells were equilibrated to 22°C and maximum 
signal was determined by total cell lysis of the positive control cells with Triton 
X-100. A volume of CytoTox-ONE Reagent equal to the volume present in each well 
(100µL) was added to each well and incubated at 22°C for 10 minutes. A volume of 
Stop Solution equal to half the volume of CytoTox-ONE Reagent used was added to 
each well and shaken for 10 seconds. The fluorescence was measured with an 
excitation wavelength of 560nm and an emission wavelength of 590nm using a 
Glomax Multi Detection System (Promega). The percent cytotoxicity of LifA was 
calculated using averaged experimental (E), maximum signal (Ms) and background 
(B) fluorescence values with the following formula:  
 
Percent cytotoxicity = (E – B)/(Ms – B) x 100 
 
 The percent cytotoxicity values for the HeLa and Jurkat cells were plotted 
against the concentration of LifA protein added with standard deviations using 
Microsoft Excel 2013. 
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2.18 Statistical analysis 
 
 The P value was generated for the T cell proliferation assay ED50s using a 






























Chapter 3: Results 
 
3.1 LifA can be secreted via Type III secretion in EPEC 
 
 Very little is known about the processing and production of LifA. Although 
Deng et al (2012) reported LifA could be secreted via the T3SS in a hypersecreting 
strain by SILAC anlysis, secretion of the full-length LifA protein has not been 
demonstrated in WT E. coli. Recently, a polyclonal rabbit antibody against highly 
purified 6xHis-tagged LifA was produced, allowing the investigation of whether 
full-length LifA protein can be secreted and the role of the LEE-encoded T3SS in 
this process. 
The WT EPEC E2348/69 strain was used to identify whether or not LifA is a 
T3S effector protein while the E2348/69 ΔlifA strain, which lacks the ability to 
produce LifA, served as a negative control. An additional strain, E2348/69 ΔescN, 
which cannot produce the T3S-associated ATPase EscN (Garmendia et al, 2004), 
was used to examine any T3S-dependent secretion of LifA. Equal quantities of 
protein in culture supernatants were loaded based on protein concentration in whole 
cell lysates. Full-length LifA was successfully detected by western blotting in the 
culture supernatant of WT E. coli E2348/69 under T3S-inducing conditions but not 
in the supernatant from the ΔlifA and ΔescN strains (Figure 3.1). 
In order to be sure that the LifA detected in the culture supernatants was 
derived solely from secretion, the proteins RecA and EspD were also probed for as 
controls. RecA is an intracellular protein (Clark and Margulies, 1965), and so should 
not be found in supernatants derived from culture of intact bacterial cells. In contrast, 
EspD is a known Type III secreted protein (Lai et al, 1997) that should not be 
present in the supernatant of the ΔescN strain, which is deficient in T3S (Garmendia 
et al, 2004). All controls worked as expected. There was no secretion of LifA 
detected in supernatants derived from the culture of the ΔescN strain even though it 
was produced in whole cell lysates of this strain, indicating that secretion of 






















Figure 3.1. Lymphostatin is secreted via the LEE-encoded T3SS in EPEC 
E2348/69. Western blot of whole cell lysates and culture supernatants for EPEC 
strains E2348/69 (WT), E2348/69 ΔlifA (ΔlifA) and E2348/69 ΔescN::KanR (ΔescN). 
Equal quantities of protein were loaded based on the protein concentration of the 
whole cell lysates. Samples were probed for LifA to analyse production and 
secretion, EspD to show that the ΔescN strain is defective in T3S, and RecA to show 
that no lysis of bacteria had occurred during the assay. Three independent assays 
were carried out and a representative blot is shown. 
 
 The average viable counts of cultures and protein concentration of the whole 
cell lysates for the WT and ΔlifA strains were similar, while the viable count and 
protein concentration for the ΔescN strain was lower (Table 3.1). 
 
Table 3.1. Average viable count of cultures and total protein concentration for 
each strain used in Figure 3.1. 
 
Strain Average viable count (CFU/mL) Total protein concentration (mg/mL) 
WT 6.75x108 2.752 
ΔlifA 5.89x108 2.273 
ΔescN 1.39x108 1.634 











Finally, it is noteworthy that there are protein species reactive to anti-LifA 
antibody that were present in the whole cell lysates of the WT and ΔescN strains but 
not present in the ΔlifA strain (Figure 3.2). It is possible that these may be processed 
or truncated forms of LifA but investigation of the nature of these bands was beyond 




















Figure 3.2. Western blot of whole cell lysates of EPEC strains using anti-LifA 
antibody. Protein species marked with arrows are not present in the ΔlifA strain, 
suggesting that these protein species may be processed or truncated forms of LifA. 
However, their function within the cell and possible secretion mechanisms remain 
unknown. Some species in the ΔlifA strain appear not to be in the WT or ΔescN 
strain but these likely correspond to the nearby bands at a slightly lower molecular 
weight. This gel was run using the same samples as Figure 3.1 but at a higher protein 
concentration. 










3.2 Generation of the pRham-LifA-6xHis DXD-AAA clone 
 
 The N-terminal portion of LifA is homologous to large clostridial toxins 
(LCTs) and contains a putative glycosyltransferase domain homologous to that in C. 
difficile toxins TcdA and B (Busch et al, 1998). LCTs contain a catalytic DXD motif 
that Busch et al (1998) reported was essential for catalysis as substitution of the 
amino acids in this motif caused an ~5000 fold decrease in enzyme activity. Given 
this homology it was hypothesized that LifA may act as a glycosyltransferase and 
that substituting the DXD motif in LifA for other residues may result in a decrease in 
the activity of LifA. In order to test this hypothesis, site-directed mutagenesis was 
used to substitute the DTD amino acid sequence that forms the DXD motif in LifA 
for an AAA sequence. AAA was chosen because alanine residues are small, 
non-polar and unreactive, which should allow the protein to fold correctly in the 
same manner as WT LifA. 
 QuikChange mutagenesis was performed using the existing 
pRham-LifA-6xHis plasmid as a template to create the AAA substitution in the lifA 
gene, which also created a new Not I restriction site in the plasmid. Different 
concentrations of template plasmid were used in separate reactions to optimise the 
yield of putative mutants. The process was controlled using a negative control 
consisting of template plasmid but no primers. The pWhitescript plasmid and 
oligonucleotide control primers were used as a positive mutagenesis control. The 
oligonucleotide control primers repair a mutation in the β-galactosidase gene, which 
can be detected by blue-white screening using a chromogenic β-galactosidase 
substrate. The pUC18 plasmid was used as a positive transformation control because 
it contains part of the E.coli lac operon, which complements the host cell’s defective 
lacqZΔM15 gene, which can be detected by blue-white screening using a 
chromogenic β-galactosidase substrate. 
Thirty of the largest colonies from across the plates with cells transformed 
with Dpn I digested DNA derived from 100 and 200ng of the original 
pRham-LifA-6xHis plasmid were cultured overnight, with only one failing to grow. 
The expected yield of colonies was 10 to 1000 colonies per plate. No colonies grew 
on the plates with cells transformed with 500ng of the original plasmid digested with 
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Dpn I or the negative control. The pWhitescript control had a mutagenesis efficiency 
of >80% and the pUC18 control had a transformation efficiency of >109 CFU/µg.  
The 29 colonies that had grown overnight were screened by colony PCR, 
using primers to amplify the full-length lifA gene and vector, and analysed by 
agarose gel electrophoresis to test whether the cells has been transformed with the 
plasmid. Out of the 29 colonies that were screened, 25 tested positive for the 
presence of the full-length plasmid (Figure 3.3). The colonies were screened against 
purified parental plasmid as a positive control and a no template negative control. To 
test whether these transformed colonies actually contained the mutant insert and 
were not simply false positives, 10 clones that tested positive for the presence of the 


















Figure 3.3. Initial screening for putative pRham-LifA-6xHis DXD-AAA mutants 
with Dpn I digested DNA from the QuikChange mutagenesis reaction. 29 
transformants of XL 10-Gold Ultracompetent cells were screened by colony PCR 
using primers that amplified the full plasmid and examined by gel electrophoresis. A 
positive control of purified pRham-LifA-6xHis plasmid was used and a no template 
sample was included as a negative control. A product of ~12kb is expected in 
positive reactions. 25 colonies were positive, 2 gave a reduced amplicon size (200/10 




































































































































































































 In designing the primers for DXD mutagenesis, it was possible to use alanine 
codons to introduce a new Not I restriction site. As there is only one other Not I 
restriction site in the parent plasmid (Figure 3.4), this makes a useful diagnostic tool 
to quickly identify putative mutant clones. Digestion of the putative mutant plasmid 
DNA was expected to give fragments of ~4 and 8kb on a gel if the plasmid was 
mutated successfully (Figure 3.4). If the mutant insert was not present, a linear single 
band of ~12kb would be expected. Five of the 10 clones tested were found to contain 
the mutant insert. The clones were screened against Not I digested and undigested 
purified template plasmid, undigested clone DNA and a no template negative 
control. It is possible that three other plasmids contained the mutation but were not 
digested by Not I to completion (200/6, 200/10 and 200/11). 
From the putative mutant clones identified, three clones were verified by 
sequencing, initially at the site of mutation to confirm that the expected sequence 
was present. Once this was confirmed, the entire lifA gene was sequenced in all three 
clones to verify that no additional mutations were introduced during the mutagenesis 
process. Although all three clones were verified to contain the appropriate mutation, 
two of the clones sequenced were found to contain additional mutations in the lifA 
gene outside the site of mutation. Only one clone was found to contain the expected 
sequence of the mutated E2348/69 lifA gene and was carried forward for further 




































Figure 3.4. Not I digestion products of purified pRham-LifA-6xHis DXD-AAA 
plasmid clones. Of the 25 colonies that tested positive for the presence of the 
pRham-LifA-6xHis DXD-AAA plasmid, 10 were selected to be screened by Not I 
digestion. Purified plasmid DNA from putative clones was digested with Not I and 
analysed by gel electrophoresis. Each sampled analysed on the gel contained 2µg of 
plasmid DNA. Undigested plasmid DNA was included as a control and digested 
parent plasmid DNA was included as a negative control. Positive clones show bands 
at ~4 and 8kb. Plasmids without the insert show a single band at ~12kb. Out of the 
10 colonies selected only 5 tested positive for the presence of the DXD-AAA insert. 
The three plasmids 200/6, 200/10 and 200/11 may have contained the DXD-AAA 
insert but were not digested completely by Not  I. 
 
3.3 Production of the LifA-6xHis DXD-AAA protein 
 
 Initially, the pRham-LifA-6xHis DXD-AAA plasmid was examined for its 
ability to produce full-length DXD-AAA LifA when induced by rhamnose. 





































































































































pRham-LifA-6xHis plasmid. Cells transformed with the pRham empty plasmid were 
used to show that LifA is only produced by cells containing the lifA gene. An 
uninduced sample from the mutant plasmid-containing cells was used to ensure that 
the DXD-AAA LifA was not being produced without being induced by rhamnose.  
LifA was detected by western blotting of crude lysates of the different strains. 
In pilot experiments, cells transformed with the mutant plasmid were capable of 
producing full-length DXD-AAA LifA when induced by the addition of rhamnose to 
the culture and the DXD-AAA LifA protein can be found in the soluble and 
insoluble fractions (data not shown). LifA was not present in the pRham empty 
plasmid-containing cells or the uninduced mutant plasmid-containing cells. 
 Once it had been verified that the clone could produce soluble DXD-AAA 
LifA, optimization of protein production was carried out. The optimal growth 
conditions for the production of WT LifA were previously determined to be growth 
in LB media incubated at 30°C for 3 hours with 0.2% (w/v) rhamnose. To determine 
the optimal growth conditions for the production of the DXD-AAA LifA protein, 
time courses were conducted using different media, temperatures and rhamnose 
concentrations. A time course using Enpresso B media, which allows cells to achieve 
a higher density than in normal media, was performed at temperatures of 20°C and 
30°C with a final rhamnose concentration of 0.2% (w/v). Samples were taken for 
SDS-PAGE at 30 minutes, 1, 2, 3 and 4 hours (Figure 3.5). This was based on the 
optimal conditions for WT LifA production. Production of DXD-LifA could be 
detected at 30°C optimally after 3 hours (Figure 3.5). Two protein species were 
observed under these conditions in Enpresso B media. Time courses using LB and 
2xTY media were also run with additional temperatures, final rhamnose 
concentrations and sample collection time points (carried out by Liz Blackburn). The 
optimal conditions for large-scale production of the DXD-AAA LifA protein was 
ultimately determined to be the same as for the WT protein (Figure 3.6). A single 
species was detected but appeared to only be 250kDa instead of the expected 
~366kDa, however, this was actually the result of running the whole cell lysates on a 















Figure 3.5. Expression time course of DXD-AAA LifA. A time course was run 
using Enpresso B media as part of determining the optimal growth conditions for 
mutant protein production. The cells were grown at either 20 or 30°C after induction 
with 0.2% (w/v) rhamnose and samples were taken at 30 minutes, 1, 2, 3 and 4 hours 
post-induction. A pre-induction sample was also taken. Incubation at 30°C for 3 
hours produced the most DXD-AAA LifA in the cells grown in Enpresso B media. 
Two protein species are seen in the optimum sample and the identity of the second 













Figure 3.6. Coomassie stain of whole cell lysates and soluble fractions of E. 
cloni® 10G transformed with the pRham-LifA-6xHis DXD-AAA plasmid grown 
at optimal conditions. The optimal conditions for mutant protein production were 
found by Liz Blackburn to be LB media at 30°C with 0.2% (w/v) rhamnose for 3 
hours, the same as for WT protein production. The protein appears to have a lower 
molecular weight than expected due to being run on a small Tris-Glycine gel rather 


































































































































































































3.4 DXD-AAA LifA purification 
 
Large-scale production of DXD-AAA LifA was carried out once the optimal 
conditions for its production were determined and the protein was isolated to a high 
purity via a five-step process, which was monitored at each step. The DXD-AAA 
LifA protein was eluted from the IMAC, SEC and ion exchange chromatography 
columns in a single absorbance peak (Figures 3.7 – 3.9). Ion exchange 
chromatography was able to separate full-length DXD-AAA LifA from truncated 
versions of the protein. The DXD-AAA LifA protein was also run through a desalt 
column before and after the ion exchange to remove excess salt. Although two 
fractions of high or lower purity were separately handled at each stage (eg. panels A 
and B of Figures 3.8 and 3.9) only the fractions of highest purity were taken forward 
for biophysical characterisation. After purification, the DXD-AAA LifA protein was 




Figure 3.7. Ion metal affinity chromatography (IMAC) purification of DXD-AAA LifA using Ni2+-sepharose. The absorbance of 
elution buffer at 280nm shows the presence of DXD-AAA LifA where the concentration of imidazole is increased from 20µM to 500µM 
(marked with an arrow) to elute the protein from the nickel-Sepharose beads. The large absorbance peak between ~0 and 250mL 
corresponds to large cell debris that do not bind the column. Inset: Coomassie stain of 5µL from 1mL IMAC filtrate fractions showing the 
DXD-AAA LifA eluted. The protein appears to have a lower molecular weight than expected due to being run on a small Tris-Glycine gel 
rather than a Tris-Acetate gel. 










































Figure 3.8. Purification of DXD-AAA LifA by size exclusion chromatography (SEC). The absorbance peaks marked with arrows 
correspond to the presence of DXD-AAA LifA in the filtrates of the Superose 6 SEC columns used to filter (A) the most pure IMAC 
fractions and (B) the less pure IMAC fractions. Inset: Coomassie stains of 5µL from 1mL SEC filtrate fractions showing the DXD-AAA 
LifA eluted. The protein appears to have a lower molecular weight than expected due to being run on a small Tris-Glycine gel rather than a 
Tris-Acetate gel. 
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Figure 3.9. Purification of DXD-AAA LifA by ion exchange chromatography. The absorbance peaks marked with arrows correspond to 
the presence of DXD-AAA LifA in the filtrates of the Mono Q columns used to filter (A) the most pure SEC fractions and (B) the less pure 
SEC fractions. The most pure and less pure fractions were pooled into separate aliquots after the ion exchange chromatography but only the 
most pure aliquot was used for further experiments. Inset: Coomassie stains of 5µL from 1mL ion exchange filtrate fractions showing the 
DXD-AAA LifA eluted. The mutant protein was eluted with 140mM NaCl (12.9% of 1M NaCl elution buffer). The small absorbance peak 
to the right of the marked peaks corresponds to truncated DXD-AAA LifA. The protein appears to have a lower molecular weight than 
expected due to being run on a small Tris-Glycine gel rather than a Tris-Acetate gel. 
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Figure 3.10. Coomassie stain of 1μg DXD-AAA LifA after second desalt. Batches 
of the most pure DXD-AAA LifA from the ion exchange chromatography were put 
through another desalt column to remove excess salt that may interfere with the 
biophysical characterisation of the protein or its sugar binding ability. The estimated 
purity of the DXD-AAA LifA protein is >90%. The protein appears to have a lower 
molecular weight than expected due to being run on a small Tris-Glycine gel rather 




















3.5 Biophysical characterisation of the purified DXD-AAA LifA 
 
 In order to determine whether the DXD-AAA LifA protein was folded and 
behaved in the same manner as the WT LifA protein, several biophysical 
measurements were carried out, including dynamic light scattering (DLS), circular 
dichroism (CD) and thermal shift assays. 
 
3.5.1 DLS shows that DXD-AAA LifA is of a similar size to WT LifA 
 
DLS was used to determine the size and state of the DXD-AAA LifA protein. 
DLS works by measuring the different intensities of laser scattering caused by the 
Brownian motion of particles in suspension. This allows protein-specific software 
supplied with the Zetasizer Auto Plate Sampler to calculate the velocity of the 
Brownian motion and therefore the size of the particles by using the Stokes-Einstein 
relationship (Malvern, 2015; Folta-Stogniew, 1999). This allows an approximate size 
determination and gives some insight into whether the protein is aggregated or 
multimeric. 
 Twelve scans of the DXD-AAA LifA protein were performed in triplicate. 
The size distribution of the protein was measured by the intensity of light scattering 
and by volume. The distribution by volume provides a more accurate size of the 
protein and distribution by the intensity of light scattering was used to detect large 
aggregates, which scatter light at much higher intensity than monomeric protein. 
Both distribution graphs have one tight peak between 9 and 30nm. The mode 
hydrodynamic radius of the DXD-AAA LifA protein as measured by intensity and 
volume is 16.24 and 13.5nm respectively (Figure 3.11). DLS confirmed that 
DXD-AAA LifA has a hydrodynamic radius of 13.5nm, similar to that of the WT 
protein (determined by Liz Blackburn). DLS also provided an approximate 
molecular weight of 358kDa for DXD-AAA LifA based on its size but this is less 
accurate than measuring the molecular weight by size exclusion 













Figure 3.11. The size distribution of DXD-AAA LifA by intensity and by 
volume, measured by dynamic light scattering (DLS). DXD-AAA LifA at a 
concentration of 1.1µM was measured by DLS to determine the size of the mutant 
protein and ensure that any loss of function was not caused by the protein forming 
large aggregates. The size distribution by volume provides a more accurate size of 
the protein than the distribution by intensity, which is primarily used to detect large 
aggregates that scatter light at a higher intensity than monomeric protein. DLS is also 
capable of providing an approximate molecular weight for the protein. The peak shift 
of the volume graph is possibly caused by random aggregation that is picked up by 
the intensity measurements but not by the volume measurements. The protein was 
scanned 12 times and the measurements were averaged. This was repeated in 
triplicate. DLS confirmed that the mutant protein has a hydrodynamic radius of 
13.5nm, similar to that of the WT protein (data not shown). Experimental data 
collection and analysis was carried out by Liz Blackburn, observed and supported by 
the candidate. 
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3.5.2 CD shows that DXD-AAA LifA has a similar secondary structure to WT LifA 
 
 CD was used to determine if the DXD-AAA LifA protein had folded 
correctly on a secondary structure level and to observe whether it deviated 
significantly from the profile obtained for the WT protein. CD works by detecting 
the difference in absorption between clockwise and anti-clockwise polarised light. 
CD signals only arise where the absorption of radiation occurs therefore spectral 
bands can be assigned to distinct structural features of a molecule. The different 
secondary structures of a protein can be detected because they give rise to 
characteristic CD spectra in the far UV (Kelly et al, 2005). 
The protein also had to be scanned by DLS before being subjected to CD 
because it was desalted into CD buffer rather than the assay buffer used in other 
experiments. CD buffer, which contains sodium fluoride rather than the sodium 
chloride used in assay buffer, had to be used for the CD experiment as chloride ions 
interfere with CD at short wavelengths. The CD profile confirmed that the 
DXD-AAA LifA had folded correctly and did not significantly differ from WT LifA 
(Figure 3.12). The mean residue ellipticity peak and trough on the graph correspond 
to the number of β-sheets and α-helices present in the protein respectively. The 
percentage of α-helices and β-sheets in DXD-AAA LifA were 31±3% and 25±4% 
respectively, compared with 37±3% and 22±3% in WT LifA. The percentage of 
turns and unstructured amino acids in DXD-AAA LifA were 15±4% and 29±5% 
respectively, compared with 13±3% and 27±6% in WT LifA. Overall, the 
DXD-AAA LifA protein was folded and had a very similar structural profile to that 
















































































Figure 3.12. Far UV spectrum of DXD-AAA LifA compared to WT LifA. 
DXD-AAA LifA at a concentration of 0.11μM was measured by CD to compare the 
secondary structure of the mutant protein with 0.11μM of the WT protein. The mean 
residue ellipticity peak between 190 and 200nm corresponds to β-sheets and the 
trough between 200 and 240nm corresponds to α-helices. Each protein was scanned 
5 times and the measurements were averaged. The data were analysed using 
DichroWeb (http://dichroweb.cryst.bbk.ac.uk/html/home.shtml; Lobley et al, 2002). 
The DXD-AAA LifA protein has a similar spectrum to that of the WT protein. WT 
LifA protein supplied by Liz Blackburn. Experimental data collected and analysis 










Helix 37±3 31±3 
Strand 22±3 25±4 
Turn 13±3 15±4 
Unstructured 27±6 29±5 
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3.5.3 Thermal shift assays show that DXD-AAA LifA has a similar mid-point 
melting temperature to WT LifA 
 
 Thermal shift assays were used to measure the thermal stability of 
DXD-AAA LifA in comparison to the WT protein. This was carried out by using a 
fluorescence-based assay using the fluorophore SYPRO orange, which fluoresces 
weakly in hydrophilic conditions and strongly in hydrophobic conditions, across a 
range of temperatures. As the temperature increases and the target protein unfolds it 
reveals hydrophobic amino acid chains that cause the SYPRO orange to increase its 
fluorescence. The fluorescence intensity is proportional to how much the protein has 
unfolded (Lo et al, 2004; Pantoliano, 2001). 
 In the first assay, using 0.1µM WT LifA and DXD-AAA LifA, the mid-point 
melting temperatures (Tm) of the WT LifA and DXD-AAA LifA proteins were 44.2 
and 43°C respectively. The second assay included the addition of 0.2µM DXD-AAA 
LifA to examine whether increasing the concentration of the protein affected the Tm. 
The Tm for the WT LifA, 0.1µM DXD-AAA LifA and 0.2µM DXD-AAA LifA were 
45.5°C, 44.2°C and 44°C respectively (Figure 3.13). Both thermal shift assays that 
were conducted showed that the DXD-AAA substitution resulted in a decrease of Tm 
of ~1°C. Increasing the concentration of the DXD-AAA LifA protein did not result 
in a significantly different Tm. This decrease in Tm was not unexpected due to 












































Figure 3.13. Thermal shift assays to evaluate the mid-point melting temperature (Tm) of WT LifA and DXD-AAA LifA. The 
fluorescence of SYPRO orange dye mixed with WT LifA and DXD-AAA LifA was measured in triplicate over a temperature range of 15 – 
70°C to determine the Tm of each protein. WT LifA at a concentration of 0.1μM and DXD-AAA LifA at concentrations of 0.1μM and 
0.2μM were compared. Each fluorescence measurement was performed in triplicate. Increasing the concentration of DXD-AAA LifA does 
not cause any significant change to the Tm. A reproducible decrease of ~1°C in the Tm of the mutant protein is observed.
 
Tm (°C) 
WT LifA 45.5±0 
0.2μM DXD-AAA LifA 44.2±0.3 
0.1μM DXD-AAA LifA 44±0 
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3.6 Mutation of the DXD motif to AAA abolished sugar binding 
 
 LCTs are known glycosyltransferases and contain a conserved DXD motif 
(Busch et al, 1998). Clostridium novyi α-toxin is known to bind uridine diphosphate 
(UDP)-N-Acetylglucosamine (GlcNAc; Selzer et al, 1996), while others such as 
Clostridium difficile enterotoxin (TcdA) bind UDP-Glucose (Glc) (Just et al, 1995). 
The DXD motif is known to be essential for activity in these molecules and is likely 
to be important in sugar-binding because it forms bonds with UDP-Glc and a 
manganese ion in the active site of TcdA (Figure 3.14; Pruitt et al, 2012). 
Recombinant WT LifA has been observed to bind UDP-GlcNAc (Stevens 
Laboratory, unpublished data) and therefore the dependence of sugar binding on the 
DXD motif contained within LifA was examined for UDP-GlcNAc and UDP-Glc. 
Changes in intrinsic tryptophan (Trp) fluorescence were used to identify the 
binding of UDP-sugars to WT and DXD-AAA LifA. The fluorescence intensity of 
Trp residues can indicate whether they are surface-bound or buried within a protein 
(Eftink and Ghiron, 1976; Price and Nairn, 2009). Intrinsic Trp fluorescence can 
either decrease via quenching (Price and Nairn, 2009) or increase (Weljie and Vogel, 
2000). Fluorescence quenching occurs when an excited Trp residue loses energy by 
either colliding with molecules in the solvent (collisional quenching) or by forming 
long-lasting interactions with molecules (static quenching; Price and Nairn, 2009). 
The exposure of each Trp residue to the quenching molecule determines how easily 
it is quenched (Eftink and Ghiron, 1976). Intrinsic Trp fluorescence increases when a 
protein undergoes a conformational change that exposes Trp residues to the solvent, 
but is stabilised by the binding of another molecule that prevents quenching (Weljie 
and Vogel, 2000). UDP-GlcNAc should therefore be able to cause a change in the 
fluorescence of Trp residues in the glycosyltransferase active site if it is able to bind 









Figure 3.14. Schematic of UDP-Glc binding in the active site of the large 
clostridial toxin (LCT) TcdA. The putative glycosyltransferase domain of LifA is 
homologous to LCTs. The glycosyltransferase domain of TcdA also contains a DXD 
motif with a DVD amino acid sequence rather than the DTD in LifA. This amino 
acid sequence forms both metal bonds with a manganese ion (yellow sphere) and 
hydrogen bonds with UDP-Glc (shown in black with bond lengths in Angstroms). It 
was hypothesised that the DTD sequence in LifA may form bonds with 
UDP-GlcNAc and an unknown metal ion, making it important for sugar-binding. 
Therefore the sequence is an ideal target for substitution in order to study whether 
LifA may act as a glycosyltransferase. UDP-Glc is the green and orange stick model, 
and the DXD motif is the blue and red stick model. The structure of TcdA was 
determined by Pruitt et al (2012). The schematic was constructed using the 
3SRZ.pdb file and Ligand Explorer (both 
http://www.rcsb.org/pdb/explore/explore.do?structureId=3SRZ), and PyMOL v1.7.6 
(http://pymol.org/). 
 
The data were produced by the candidate, with the exception of WT LifA and 
UDP-GlcNAc (carried out by Liz Blackburn), and analysed using the law of mass 
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action and the Stern-Volmer relationship (data analysis was carried out by Liz 
Blackburn). The addition of increasing concentrations of UDP-GlcNAc to WT LifA 
causes the intrinsic Trp fluorescence to increase before decreasing after the 
concentration of UDP-GlcNAc is increased beyond ~250µM (Figure 3.15A), 
indicating that WT LifA binds UDP-GlcNAc. An increase in UDP-GlcNAc 
concentration causes an increase in sugar-binding. The addition of UDP-Glc to WT 
LifA or either UDP-sugar to DXD-AAA LifA results in a gradual decrease in 
fluorescence, indicating that no sugar-binding is occurring, since collisional 
quenching causes the fluorescence to decrease over time. The binding of 
UDP-GlcNAc to WT LifA is seen as a curve on the Stern-Volmer plot (Figure 
3.15B/C), whereas the lack of binding of UDP-Glc and WT LifA as well as both 
UDP-sugars with DXD-AAA LifA is evident as straight lines. The Stern-Volmer plot 
displays the fluorescence of the solution in the absence of UDP-GlcNAc divided by 
the fluorescence in the presence of UDP-GlcNAc, against the concentration of 
UDP-GlcNAc added to the solution. In the absence of the DXD motif, UDP-GlcNAc 









































Figure 3.15. Sugar binding to WT LifA and DXD-AAA LifA. UDP-GlcNAc and 
UDP-Glc were titrated against 0.05μM WT LifA and DXD-AAA LifA and the 
intrinsic Trp fluorescence was measured in triplicate at 340nm. F0 and F denote the 
fluorescence of the solution in the absence and presence of UDP-sugar respectively. 
(A) Example of raw data of the intrinsic Trp fluorescence of WT LifA against 
increasing concentrations of UDP-GlcNAc. (B) Stern-Volmer plot of the intrinsic 
Trp fluorescence of WT LifA against increasing concentrations of UDP-GlcNAc and 
UDP-Glc. (C) Stern-Volmer plot of the intrinsic Trp fluorescence of DXD-AAA 
LifA against increasing concentrations of UDP-GlcNac and UDP-Glc. There is a 
marked loss of UDP-GlcNAc binding to the DXD-AAA LifA protein. Experiments 
examining WT LifA with UDP-GlcNac were carried out by Liz Blackburn. 
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3.7 T cell proliferation assays 
 
 It has been observed that cell lysates containing LifA inhibit the 
mitogen-stimulated proliferation of peripheral blood lymphocytes (Klapproth et al, 
1995; Klapproth et al, 1996; Malstrom and James, 1998; Klapproth et al, 2000; 
Stevens et al, 2002). In addition, our laboratory recently showed that purified 
recombinant WT LifA also inhibits mitogen-stimulated proliferation of bovine T 
cells. As a result, this is an ideal system to test whether the DXD motif is essential 
for the biological activity of LifA against T cells. 
 Peripheral blood T lymphocytes from 3 independent donors were used to test 
the activity of purified DXD-AAA LifA against ConA-stimulated T cells in 
comparison to the WT LifA protein using a colourimetric plate-based assay. The 
assay measures the conversion of an MTS tertrazolium compound into a coloured 
formazan product by metabolically active cells, the absorbance of which can be 
detected at around 490nm. The quantity of formazan produced is directly 
proportional to the metabolic activity of dividing cells in the culture (Promega, 
2012). 
 Titration of WT LifA produces a sigmoid curve, with higher concentrations 
of LifA causing an increase in inhibition (Figure 3.16). The ratio of proliferation of 
cell treated with LifA+ConA/ConA alone decreases sharply from 0.98±0.11 at 
0.001ng/mL of WT LifA to 0.41±0.04 at 0.1ng/mL, then the curve levels out and 
decreases to a ratio of 0.3±0.07 at 100ng/mL. DXD-AAA LifA produces a curve that 
sees the ratio of LifA+ConA/ConA alone gradually decrease from 1.01±0.09 at 
0.1ng/mL to 0.49±0.15 at 10µg/mL. It requires an ~100,000 fold increase in 
concentration for the DXD-AAA LifA protein to have the same inhibitory effect as 
that of the WT protein. The effective dose at which 50% of lymphocyte proliferation 
is inhibited (ED50) was 0.014±0.006 for WT LifA and 304.1±16.9ng/mL for 
DXD-AAA LifA (P value < 0.05). The buffer that the DXD-AAA LifA was 
dissolved in did not have any effect on the assay. The addition of ConA resulted in 
an average 3-fold increase of T cell proliferation above the negative control across 
the 3 experimental repeats. 
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Figure 3.16. Concentration titration of recombinant WT LifA and DXD-AAA LifA against ConA-stimulated peripheral bovine T 
lymphocytes. An absolute number of 200,000 cells were seeded into the wells of a 96 well plate. Titrations were carried out in triplicate 
and the results are the average obtained from 3 independent experiments using 3 donors. Error bars indicate the standard deviation of the 





































3.8 Cytotoxicity assays 
 
 The LCTs are well known to have a cytotoxic effect on enterocytes 
(Triadafilopoulos et al, 1987), however, there is no formal evidence that LifA has a 
direct cytotoxic effect on mammalian cells. As a result, cytotoxicity assays were 
performed using recombinant WT LifA. As the two main cell types affected by LifA, 
the adherent HeLa cell line was used as a model for epithelial cells and the 
suspension Jurkat cell line was used as a model for T cells. 
Release of the intracellular protein lactate dehydrogenase (LDH) can be used 
as a marker of cytotoxicity. Here, a fluorometric plate-based assay was used to 
measure LDH release (Promega, 2009). The mechanism of LDH detection can be 


















Figure 3.17. Mechanism of fluorescence caused by LDH release. Cells with a 
compromised membrane activity release LDH. This drives the conversion of NAD+ 
to NADH in the conversion of lactate to pyruvate, which is coupled to a reaction that 
converts resazurin to the fluorescent product resorufin in the CytoTox-ONE substrate 
mix. The generation of fluorescent resorufin is proportional to the quantity of LDH 
released (adapted from Promega, 2009). 
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At both 24 and 48 hours of incubation of cells with LifA, no sign of 
cytotoxicity was observed. At 24 hours incubation, the percent cytotoxicity observed 
with the HeLa and Jurkat cell negative controls was 32.6±18.1% and 9.6±3.2% 
respectively at buffer dilutions equivalent to 10µg/mL LifA. In the presence of LifA 
at 10µg/mL the percent cytotoxicity was 10.7±2% for the HeLa cells and 31.4±15% 
for the Jurkat cells. After 48 hours incubation, the percent cytotoxicity observed with 
the HeLa and Jurkat cell negative controls was 13.9±3.1% and 24.7±13.4% 
respectively at buffer dilutions equivalent to 10µg/mL LifA. In the presence of LifA 
at 10µg/mL the percent cytotoxicity was 12.3±4.2% for the HeLa cells and 
18.8±10.3% for the Jurkat cells.  (Figure 3.18). In addition, a 
concentration-dependent titration of the protein had no significant effect on LDH 
release. The results are an average of 3 experimental repeats carried out in triplicate. 
Regardless of the concentration, the percent cytotoxicity of LifA did not significantly 
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Jurkat+LifA HeLa+LifA
Figure 3.18. Cytotoxicity of WT LifA against HeLa and Jurkat cells. An absolute number of 25,000 cells of each cell type were seeded 
into the wells of a 96 well opaque sided plate. After incubation with the protein, the percent cytotoxicity of cells at each protein 
concentration, as well as negative controls, were calculated in comparison to a positive control of maximum possible cell lysis. (A) 
Cytotoxicity at 24 hours. (B) Cytotoxicity at 48 hours. Titrations were carried out in triplicate and the results are an average of 3 
independent experiments. Error bars indicate the standard deviation of the average percent cytotoxicity from across the 3 experiments.
(A) (B) 
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Chapter 4: Discussion 
 
LifA is a large multifunctional protein produced by EPEC and non-O157 
EHEC. Although its ability to act as an adhesin and to inhibit the mitogen-stimulated 
proliferation of lymphocytes and cytokine expression are well documented, little has 
been done to identify exactly how it functions in the 20 years since its effects were 
first recorded by Klapproth et al (1995). This has most likely been due the inability 
to produce stable cloning vectors containing the full-length lifA gene (Klapproth et 
al, 2000; Nicholls et al, 2000; Janka et al, 2002). Recent advances in understanding 
the mode of action of LifA have allowed for the findings reported in this study. 
The mechanism(s) of LifA secretion is poorly understood and must be 
addressed to better understand how LifA is able to act as both a lymphostatin and an 
adhesin. In this study, the ability of full-length LifA to be secreted via the 
LEE-encoded T3SS was investigated. This study has shown for the first time that 
full-length LifA is a Type III secreted effector protein under in vitro conditions in 
WT E. coli O127:H6 E2348/69. Full-length LifA was detected in the culture 
supernatant of the WT strain under T3S-inducing conditions but not in the ΔescN 
strain that lacks the T3SS ATPase. The LifA species detected on the western blots 
appeared much fainter than other T3S proteins such as EspD, which suggests that 
LifA may be secreted in lower quantities than these proteins, however, reactivity is a 
function of antibody affinity and avidity and may not reflect absolute quantities. The 
RecA control confirmed that secretion of LifA was not the product of cell lysis. 
Although this finding suggests that LifA may enter enterocytes via translocation 
through the T3SS, it does not explain how the protein enters lymphocytes, which E. 
coli may not encounter with the same frequency. LifA does not necessarily need to 
be secreted directly into host cells since Type III secretion is not contact dependent 
in E. coli (Kenny et al, 1997b). Thus, some LifA may be injected into cells and some 
may be secreted into the extracellular milieu by T3SS needle complexes not in 
contact with host cells. Overall, this study advances our understanding of the 
secretion of LifA as very little was known about the secretion mechanism(s) of LifA 
until Deng et al (2012) reported that it appeared to be secreted via the T3SS by 
SILAC analysis, which mapped peptides across the protein. These authors confirmed 
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that the N-terminal 50 – 100 amino acids were necessary and sufficient to direct 
secretion of a TEM-1 β-lactamase reporter. This amino acid sequence was chosen 
because as little as 20 amino acids from the N-terminus of various Type III secreted 
proteins are required to mediate translocation of these proteins through the T3SS 
(Charpentier and Oswald, 2004). Deng et al (2012) also used a hypersecreting EPEC 
E2348/69 strain in their experiments and suggested that LifA may only be detectable 
under hypersecreting conditions. This study has proven that a hypersecreting strain is 
not necessary to detect LifA and that it can in fact be detected in WT bacteria using 
our LifA-specific antiserum. 
A possible improvement to this experiment would be to use DMEM as a 
culture medium to induce Type III secretion, as performed by Deng et al (2012), 
rather than MEM to improve the yield of LifA that is secreted. Nicholls et al (2000) 
tested the effects of different media on the expression of a LifA-PhoA fusion and 
found that Todd-Hewitt broth was the most effective liquid medium for increasing 
the expression of LifA in EHEC O111:H- E45035N. To achieve optimal LifA 
secretion, time courses could be run under different T3S-inducing conditions to find 
which media allows the bacteria to secrete the maximum quantity of LifA before 
lysing. 
 Although LifA was not detected in the culture supernatant of the ΔescN 
strain, this does not mean that undetectable quantities of LifA are not being secreted 
via other mechanisms. There is evidence to suggest that LifA is not strictly 
dependent on Type III secretion for activity. For instance, cell lysates containing 
LifA, including laboratory-adapted strains lacking a T3SS, and purified LifA protein 
have been observed to inhibit the mitogen-stimulated proliferation of T lymphocytes 
(Klapproth et al, 1995; Klapproth et al, 1996; Klapproth et al, 2000; Stevens et al, 
2002). A future question to be addressed is how LifA enters target cells when not 
injected directly as above. It may be that LifA can be both translocated into cells and 
enter through receptor-mediated endocytosis or other uptake pathways. It is difficult 
to postulate the exact mechanism of cell entry of LifA considering that its target 
protein(s) remains unknown. In order to investigate how LifA is taken up by host 
cells, specific inhibitors that target different endocytic pathways could be used to 
examine their impact on LifA activity. For instance, bafilomycin could be used to 
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study the potential requirement for endosome acidification for the escape of LifA 
from entry vesicles, as is the case for LCTs (Schirmer and Aktories, 2004). In order 
to understand the mechanism(s) of activity of LifA it is critical to identify its host 
cell binding partners. Putative protein-protein interactions could be identified by 
far-western blotting and/or immuno-precipitation studies using cell lysates treated 
with recombinant LifA. Affinity chromatography, whereby recombinant LifA could 
be bound to a column via the 6xHis tag, could also be used to isolate binding 
partners. Putative binding partners could then be identified using mass spectrometry. 
The yeast two-hybrid system may also be useful for examining the interactions 
between purified suspected binding partners and LifA. 
Western blotting for LifA detected protein species present in the supernatant 
of WT EPEC and ΔescN strains that the ΔlifA strain lacked. It is possible that these 
correspond to shortened versions LifA that are secreted by other mechanisms. The 
identification of these protein species was outwith the scope of this study but 
discerning their identity could be grounds for future study. N-terminal sequencing 
could be used in conjunction with bioinformatic approaches to identify a Sec- or 
Tat-peptide signal sequence indicative of Type II secretion (Filloux, 2010; von 
Heijne, 1990; Voulhoux et al, 2001). 
While this study has detected LifA secretion under T3S-inducing in vitro 
conditions, future research could seek to determine whether LifA production and/or 
translocation could be detected in the gut of infected animals using reporter fusions 
(as was carried out by Geddes et al (2007) for Salmonella Type III secreted proteins) 
or LifA antiserum. Another area to address is why LifA mutations have an indirect 
post-transcriptional effect on the expression and secretion of other T3S proteins, such 
as EspA and Tir in some strains (Stevens et al, 2002). It is possible that it may be 
involved in the hierarchy of secretion of T3S proteins (Wang et al, 2008; Mills et al, 
2013). 
LifA’s homology with LCTs, including the catalytic DXD motif, suggests 
that the protein may act at least in part as a glycosyltransferase. In order to test this 
hypothesis a mutant variant of the pRham-LifA-6xHis plasmid was successfully 
created during this study, replacing the DTD amino acid sequence in the DXD motif 
with an AAA sequence. An AAA sequence was chosen for the substitution because 
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alanine residues are small, non-polar and unreactive. Similar experiments were 
performed by Deacon et al (2010), in which a DXD-AAA substitution was created in 
the lifA gene on the chromosome of EHEC O26:H- rather than on a plasmid vector as 
in this study. It was found that the colonisation of cattle by EHEC O26:H- was 
dependent on LifA but not the DXD motif, however, when the mutation was 
transferred to the chromosome of EPEC O127:H6 E2348/69, the DXD motif was 
found to be required for lymphostatin activity, albeit in a relatively insensitive assay 
reliant on crude bacterial lysates. The latter observation is consistent with the 
observations made in this study although Deacon et al (2010) did not make a 
connection between the LifA protein’s function and its sugar binding ability. It is 
possible that the DXD motif was not required for the effective colonisation of cattle 
as other activities of LifA exist, for example in promoting adherence, although no 
defect in adherence to HeLa cells was observed by Deacon et al (2010). 
The creation of the pRham-LifA-6xHis DXD-AAA plasmid provides a useful 
tool alongside the existing pRham-LifA-6xHis plasmid for producing recombinant 
LifA proteins that can be used to examine both the sugar binding ability and function 
of LifA as a lymphostatin. 
In order to ensure that the purified DXD-AAA LifA protein  was as similar to 
the WT recombinant LifA as possible, the DXD-AAA LifA protein was subjected to 
three different biophysical characterisation experiments. Dynamic light scattering 
confirmed that the DXD-AAA LifA protein was monomeric by measuring the 
hydrodynamic radius of the protein. Circular dichroism (CD) confirmed that the 
DXD-AAA LifA protein had a similar secondary structure to that of the WT protein. 
The CD spectrum of DXD-AAA LifA was not an exact copy of the spectrum for WT 
LifA and in particular the percentage of the secondary structure consisting of 
α-helices appeared to be slightly reduced. However, the error values for each 
structural motif in the WT and DXD-AAA LifA proteins overlap and so the 
differences in percentages are acceptable. Thermal shift assays confirmed that the 
DXD-AAA LifA protein has a similar Tm to that of the WT protein. A reproducible 
decrease in the Tm of DXD-AAA LifA of ~1°C was observed, which is not 
unexpected since changing the active site of the protein may result in the loss of the 
putative metal ion. Assuming that the metal ion also binds to other amino acids in the 
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active site as it does in TcdA (Pruitt et al, 2013), its loss would result in an overall 
loss of some structural stability. These experiments were performed to ensure that 
the results seen in future experiments were genuine and not due to the incorrect 
synthesis and folding of the DXD-AAA LifA protein. 
Previous experiments with LifA have shown that it is capable of binding 
UDP-GlcNAc but not UDP-Glc (Stevens Laboratory, unpublished data). These 
particular UDP-sugars were chosen as they are both known to bind LCTs (Schirmer 
and Aktories, 2004). For the first time, the ability of LifA to bind UDP-GlcNAc has 
been shown in this study to be dependent on the DXD motif. This was done by 
comparing the ability of both WT and DXD-AAA LifA to bind UDP-GlcNAc and 
UDP-Glc. The sugar binding ability of these proteins was examined by measuring 
changes in the intrinsic tryptophan (Trp) fluorescence of the proteins in the presence 
of each UDP-sugar. Trp fluorescence quenching is commonly used to identify 
interactions between proteins and ligands when there are Trp residues at the 
suspected binding pocket, but becomes less sensitive with more Trp residues (Price 
and Nairn, 2009). There are seven Trp residues in proximity to the 
glycosyltransferase binding pocket in LifA, making specific interactions between the 
protein and the UDP-GlcNAc more difficult to detect. However, the fluorescence of 
WT LifA instead increases in the presence of UDP-GlcNAc, which is likely to be 
caused by a conformational change in the protein that is stabilised by UDP-GlcNAc 
binding (Weljie and Vogel, 2000). 
It is possible that sugar binding is dependent on the presence of a metal ion in 
the active site as seen in TcdA from C. difficile (Pruitt et al, 2012). However, it has 
not yet been shown that sugar binding in LifA is dependent on a metal ion. A 
possible method to identify the putative metal ion would be to subject the 
glycosyltransferase domain of LifA to X-ray crystallography in a similar manner as 
to how Pruitt et al (2012) determined the structure of TcdA. However, Pruitt et al 
(2012) artificially introduced manganese to TcdA. Since the putative metal ion of 
LifA could be lost or replaced during the production and purification process or LifA 
may bind multiple different metal ions, crystallography would have to be performed 
using different metals to find which ones bind. To date, UDP-GlcNAc binding and 
thermal stability have not proven sensitive to different exogenous metal ions but it is 
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possible the recombinant protein acquired metal ions during expression and/or 
purification. The binding of UDP-GlcNAc to LifA is not actually indicative of sugar 
transfer and so a sugar hydrolysis assay could be used in future work to determine if 
UDP-GlcNAc is the natural substrate of LifA. Other UDP-sugars should also be 
tested for their ability to bind LifA. While most LCTs bind only UDP-Glc, C. novyi 
α-toxin is capable of binding UDP-GlcNAc and UDP-Glc, but to a much lesser 
extent (Schirmer and Aktories, 2004; Busch et al, 2000). It is therefore conceivable 
that LifA may be capable of binding multiple UDP-sugars. If this is the case we can 
also then determine whether the binding of these UDP-sugars is DXD dependent.  
This study has shown that the DXD motif is important for the function of 
LifA to inhibit the mitogen-stimulated proliferation of bovine T lymphocytes. The 
ED50 of the DXD-AAA LifA was ~10,000 fold greater than the ED50 of the WT LifA 
protein but activity may not have been abolished altogether. Whether the ability of 
DXD-AAA LifA to inhibit T cell proliferation at high concentrations reflects 
residual activity or the presence of co-purified proteins or contaminants requires 
further study. Indeed, even lysates of E. coli lacking LifA become inhibitory to 
bovine PBMCs if used at high concentrations. There are multiple reasons why 
mutation of the DXD motif could fail to completely abolish the ability of LifA to 
inhibit the mitogen-stimulated proliferation of T cells: the DXD-AAA LifA protein 
could still be able to bind small amounts of UDP-GlcNAc that are not detected by 
the sugar binding assays; the protein is capable of binding other UDP-sugars; or LifA 
may not act solely as a glycosyltransferase. 
 Given that LifA binds UDP-GlcNAc, and that the DXD motif is important for 
this activity, it is likely that LifA acts as a glycosyltransferase to arrest lymphocyte 
proliferation. A future goal would be to attempt to identify the target protein(s) of 
glycosyltransferase activity. This would be challenging, however, due to the 
abundance of proteins in mammalian cells that are capable of accepting GlcNAc. A 
possible method for identifying the glycosylation target would be to mix radiolabeled 
UDP-GlcNAc with purified WT LifA and add this mix to T cell lysates. The size of 
the T cell proteins that have been glycosylated with radiolabeled GlcNAc could be 
determined by autoradiography. Western blotting using antibodies against 
O-GlcNAc is an alternative to autoradiography but the O-GlcNAc proteome of 
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mammalian cells is likely to be complex and we cannot be certain that GlcNAc is 
transferred to an O-linkage. Shot-gun quantitative mass spectrometry could also be 
used to look for proteins that shift in size by the mass of UDP-GlcNAc, accounting 
for different linkage types and the possible addition of multiple GlcNAc molecules. 
Once protein binding partners have been identified, recombinant forms could be 
made and mixed with purified LifA and labelled UDP-GlcNAc to confirm the 
glycosylastion of putative target proteins. This method was used to identify the 
glycosyltransferase targets of NleB (Li et al, 2013; Pearson et al, 2013). NleB serves 
as potential model for LifA activity as it is a T3S effector protein, it contains a DXD 
motif and binds UDP-GlcNAc, and it inhibits the expression of pro-inflammatory 
cytokines without acting as a cytotoxin (Gao et al, 2013; Li et al, 2013; Pearson et 
al, 2013). 
Despite LifA’s homology with LCTs, which are known to act as cytotoxins 
by transferring UDP-sugars onto Rho GTPases (Triadafilopoulos et al, 1987; Just et 
al, 1995; Selzer et al, 1996), LifA itself has never been observed to act as a cytotoxin 
against T cells or epithelial cells (Klapproth et al, 1995; Stevens et al, 2002). These 
experiments used crude bacterial lysates, however, and so in this study, purified 
recombinant LifA was examined for its potential cytotoxic effects using a 
fluorometric LDH release assay. Consistent with the previous experiments, this study 
has shown that the addition of LifA to either HeLa (epithelial cell model) or Jurkat 
(T cell model) cells does not cause any obvious direct cytotoxic effects to these cell 
types. Moreover, no direct cytotoxicity has been observed against bovine T cells 
during lymphostatin assays, indicating that inhibition of proliferation does not 
involve killing (Stevens Laboratory, unpublished data). This contrasts with the 
observations by Babbin et al (2009) that suggest that LifA produced by C. rodentium 
targets Rho GTPases in mice. However, the actin cytoskeleton did not collapse in a 
manner similar to that of LCTs but rather tight junctions and subjacent adherens 
junctions between host cells were disrupted. Deacon et al (2010) attempted to 
replicate the observation that LifA targets Rho GTPases but did not observe any 
increase in RhoA activation in cells infected with EPEC O127:H6 strain E2348/69, 
EHEC O26:H- strain 193 nalR or LifA null mutants of these strains. It does not seem 
that LifA necessarily acts as a direct cytotoxin or as a cytotoxin at all. An example of 
 82 
a non-cytotoxic glycosyltransferase is NleB, a T3S effector of EPEC and EHEC, 
which binds UDP-GlcNAc and GlcNAcylates an arginine residue on the TRADD 
death domain host receptor (Li et al, 2013; Pearson et al, 2013). This disrupts tumour 
necrosis factor signalling in EPEC-infected cells including NF-κB signalling and 
apoptosis (Li et al, 2013; Pearson et al, 2013). It seems plausible that LifA may act 
in a manner akin to NleB, whereby it targets signalling pathways to inhibit both 
lymphocyte proliferation and cytokine expression, and experiments are planned to 
determine if LifA acts on key signal transduction pathways. A possible future 
experiment would be to use ATP assays rather than LDH release assays. This would 
allow the quantity of energy actually available in LifA treated cells to be measured 
and indicate whether the cells are healthy even though they are intact. 
 It is of interest to examine the localisation of LifA inside and on the surface 
of both bacterial and mammalian cells. This would give further insight into where the 
target protein(s) of LifA is located and also how LifA acts as an adhesin. The 
localisation of LifA in bacterial cells could be analysed by fractionating bacterial 
whole cell lysates and examining the different cell compartments for LifA using 
western blotting. Alternatively, fluorescent or confocal microscopy could be used to 
detect recombinant LifA in or on cells using fluorescently labelled anti-His tag 
antibodies. 
Due the success in this study of substituting the DXD motif with an AAA 
sequence, other regions could be substituted using QuikChange mutagenesis. This 
technique could be used to mutate other areas of the glycosyltransferase domain to 
determine how important they are. Alternatively, this technique could be used to 
make mutations in the putative cysteine protease domain of LifA in order to 
determine whether it is necessary for the function of LifA. Mutated LifA proteins 
could be compared against WT LifA in their ability to inhibit T cell proliferation. 
 To determine which parts of the LifA protein are required for activity, nested 
truncations or linker scanning mutagenesis could be used to generate fragments of 
LifA. These fragments could be mixed in different combinations and used in T cell 
proliferation assays to determine whether particular combinations of LifA fragments 
can exhibit activity or whether the protein must be whole in order to function. 
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 The ability of LifA to act as an adhesin has not been the focus of this study 
but it is still an interesting point to consider for future work. Adhesion assays could 
be used to examine the ability of LifA to mediate adherence to epithelial cells. E. coli 
lab strains transformed with the pRham-LifA-6xHis plasmid and the E2348/69 ΔlifA 
strain could be compared in their ability to adhere to HeLa cells using light 
microscopy and viable counts of bound bacterial cells. The ΔlifA strain could also be 
transformed with the pRham-LifA-6xHis plasmid to see if the plasmid can restore 
adherence. Alternatively, mixing recombinant LifA with lab strains and HeLa cells 
could be used to see if the bacteria show an increase in adherence. Dominant 
adhesins such as intimin and BFP may mask a subtle role played by LifA, as 
previously found in masking the role of EspA (Cleary et al, 2004), and so would 
have to be non-functional to see the effects of LifA as an adhesin. 
 Future research could also focus on areas that are not directly related to LifA 
function. The role of the truncated LifA and ToxB in EHEC O157:H7 as well as the 
Chlamydia cytotoxins could be investigated for instance. Both LifA and ToxB were 
found to be Type III secreted by Deng et al (2012) but LifA lacks the DXD motif. 
Abu-Median et al (2006) found that both these proteins did not have 
lymphostatin-like activity but the assays used were insensitive and relied on crude 
bacterial lysates. With the ability to make stable plasmid clones of these proteins, 
LifA homologues could be examined for both lymphostatin-like activity and 
UDP-sugar binding. This study and previous publications have primarily used 
mitogens to stimulate the proliferation of lymphocytes in lymphostatin assays, 
however, it is unlikely that lymphocytes would encounter such chemicals in vivo. 
Re-stimulating the lymphocytes with antigens, as performed by Malstrom and James 
(1998), would be more reflective of how LifA actually functions during an infection. 
Another avenue of research would be to investigate whether LifA interferes with the 
development of adaptive immunity against EPEC and EHEC during infection, for 
example, by immunisation with a model antigen. 
 Continued studies of the molecular basis of lymphostatin activity have the 
potential to reveal novel biology, both in understanding bacterial virulence and the 





Abu-Median, A., van Diemen, P.M., Dziva, F., Vlisidou, I., Wallis, T.S. and Stevens, 
M.P. (2006). Functional Analysis of Lymphostatin Homologues in 
Enterohaemorrhagic Escherichia coli. FEMS Microbiology Letters 258, 43–49. 
Acheson, D.W., Moore, D., de Breuker, S. Lincicome, L., Jacewicz, M., Skutelsky, 
E. and Keusch, G.T. (1996). Translocation of Shiga Toxin Across Polarized 
Intestinal Cells in Tissue Culture. Infection and Immunity 64, 3294–3300. 
Agilent Technologies (2015). QuikChange II XLSite-Directed Mutagenesis Kit 
Instruction Manual. 
Andrade, A., Pardo J.P., Espinosa, N., Pérez-Hernández, G. and González-Pedrajo, 
B. (2007). Enzymatic Characterization of the Enteropathogenic Escherichia coli 
Type III Secretion ATPase EscN. Archives of Biochemistry and Biophysics 468, 
121–127. 
Asakura, H., Kawamoto, Y., Haishima, Y., Igimi, S., Yamamoto, S. and Makino, S. 
(2008). Differential Expression of the Outer Membrane Protein W (OmpW) 
Stress response in Enterohemorrhagic Escherichia coli O157:H7 Corresponds to 
the Viable but Non-Culturable State. Research in Microbiology 159, 709–717. 
Babbin, B.A., Sasaki, M, Gerner-Schmidt, K.W., Nusrat, A. and Klapproth, J.A. 
(2009). The Bacterial Virulence Factor Lymphostatin Compromises Intestinal 
Epithelial Barrier Function by Modulating Rho GTPases. The American Journal 
of Pathology 174, 1347–1357. 
Badea, L., Doughty, S., Nicholls, L., Sloan, J., Robins-Browne, R.M. and Hartland, 
E.L. (2003). Contribution of Efa1/LifA to the Adherence of Enteropathogenic 
Escherichia coli to Epithelial Cells. Microbial Pathogenesis 34, 205–215. 
 
 85 
Baruch, K., Gur-Arie, L., Nadler, C., Koby, S., Yerushalmi, G., Ben-Neriah, Y., 
Yogev, O., Shaulian, E., Guttman, C., Zarivach, R. and Rosenshine, I. (2011). 
Metalloprotease Type III Effectors that Specifically Cleave JNK and NF-κB. 
The EMBO Journal 30, 221–231. 
Belland, R.J., Scidmore, M.A., Crane, D.D., Hogan, D.M., Whitmire, W., McClarty, 
G. and Caldwell, H.D. (2001). Chlamydia trachomatis Cytotoxicity Associated 
with Complete and Partial Cytotoxin Genes. Proceedings of the National 
Academy of Sciences of the United States of America 98, 13984–13989. 
Bentley, R. and Meganathan, R. (1982). Biosynthesis of Vitamin K (Menaquinone) 
in Bacteria. Microbiological Reviews 46, 241–280. 
Berger, C.N., Crepin, V.F., Baruch, K., Mousnier, A., Rosenshine, I., Frankel, G. 
(2012). EspZ of Enteropathogenic and Enterohemorrhagic Escherichia coli 
Regulates Type III Secretion System Protein Translocation. mBio 3, 1–12. 
Bieber, D., Ramer, S.W., Wu, C., Murray, W.J., Tobe, T., Fernandez, R. and 
Schoolnik G.K. (1998). Type IV Pili, Transient Bacterial Aggregates, and 
Virulence of Enteropathogenic Escherichia coli. Science 280, 2114–2118. 
Blasche, S., Mörtl, M., Steuber, H., Siszler, G,. Nisa, S., Schwarz, F., Lavrik, I., 
Gronewold, T.M.A., Maskos, K., Donnenberg, M.S., Ullman, D., Uetz, P. and 
Kögl, M. (2013). A Next-Generation Approach to the Characterization of a 
Non-Model Plant Transcriptome. PLOS ONE 8, p.e58937. 
Blattner, F., Plunkett III, G., Bloch, C.A., Perna, N.T., Burland, V., Riley, M., 
Collado-Vides, J., Glasner, J.D, Rode, C.K., Mayhew, G.F., Gregor, J., Davis, 
N.W., Kirkpatrick, H.A., Goeden, M.A., Rose, D.J., Mua, B. and Shao, Y. 




Brady, M.J., Campellone, K.G., Ghildiya, M. and Leong, J.M. (2007). 
Enterohaemorrhagic and Enteropathogenic Escherichia coli Tir Proteins Trigger 
a Common Nck-Independent Actin Assembly Pathway. Cellular Microbiology 
9, 2242–2253. 
Brooks, J.T., Sowers, E.G., Wells, J.G., Greene, K.D., Griffin, P.M., Hoekstra, R.M. 
and Stockbine, N.A. (2005). Non-O157 Shiga Toxin-Producing Escherichia coli 
Infections in the United States, 1983-2002. The Journal of Infectious Diseases 
192, 1422–1429. 
Burland, V., Shao, Y., Perna, N.T., Plunkett, G., Sofia, H.J., and Blattner, F.R. 
(1998). The Complete DNA Sequence and Analysis of the Large Virulence 
Plasmid of Escherichia coli O157:H7. Nucleic Acids Research 26, 4196–4204. 
Busch, C., Hofmann, F., Selzer, J., Munro, S., Jeckel, D. and Aktories, K. (1998). A 
Common Motif of Eukaryotic Glycosyltransferases is Essential for the Enzyme 
Activity of Large Clostridial Cytotoxins. The Journal of Biological Chemistry 
273, 19566–19572. 
Busch, C., Schömig, K., Hofmann, F. and Aktories, K. (2000). Characterization of 
the Catalytic Domain of Clostridium novyi Alpha-Toxin. Infection and 
Immunity 68, 6378–6383. 
Buttner, D. (2012). Protein Export According to Schedule: Architecture, Assembly, 
and Regulation of Type III Secretion Systems from Plant- and 
Animal-Pathogenic Bacteria. Microbiology and Molecular Biology Reviews, 76, 
262–310. 
Campellone, K.G. and Leong, J.M. (2005). Nck-Independent Actin Assembly is 
Mediated by Two Phosphorylated Tyrosines Within Enteropathogenic 
Escherichia coli Tir. Molecular Microbiology 56, 416–432. 
Carlucci, A.F. and Pramer, D. (1959). Factors Affecting the Survival of Bacteria in 
Sea Water. Microbiological Progress Report 7, 388–392. 
 87 
Charpentier, X. and Oswald, E. (2004). Identification of the Secretion and 
Translocation Domain of the Enteropathogenic and Enterohemorrhagic 
Escherichia coli Effector Cif, using TEM-1 β-Lactamase as a New 
Fluorescence-Based Reporter. Journal of Bacteriology 186, 5486–5495. 
Clark, A.J. and Margulies, D. (1965). Isolation and Characterization of 
Recombination-Deficient Mutants of Escherishia coli K12. Proceedings of the 
National Academy of Sciences of the United States of America 53, 451–459. 
Cleary, J., Lai, L., Shaw, R.K., Straatman-Iwanoska, A., Donnenberg, M.S., Frankel, 
G. and Knutton, S. (2004). Enteropathogenic Escherichia coli (EPEC) Adhesion 
to Intestinal Epithelial Cells: Role of Bundle-Forming Pili (BFP), EspA 
Filaments and Intimin. Microbiology 150, 527–538. 
Costa, T.R.D., Felisberto-Rodrigues, C., Meir, A., Prevost, M.S., Redzej, A., 
Trokter, M. and Waksman, G. (2015). Secretion Systems in Gram-Negative 
Bacteria: Structural and Mechanistic Insights. Nature Reviews Microbiology 13, 
343–359. 
Creasey, E.A., Delaha, R.M., Daniell, S.J and Frankel, G. (2003). Yeast Two-Hybrid 
System Survey of Interactions Between LEE-Encoded Proteins of 
Enteropathogenic Escherichia coli. Microbiology 149, 2093–2106. 
Crepin, F., Shaw, R., Abe, C.M., Knutton, S. and Frankel, G. (2005). Polarity of 
Enteropathogenic Escherichia coli EspA Filament Assembly and Protein 
Secretion. Journal of Bacteriology 187, 2881–2889. 
Croxen, M..A and Finlay, B.B. (2010). Molecular Mechanisms of Escherichia coli 
Pathogenicity. Nature Reviews Microbiology 8, 26–38. 
Daniell, S.J., Koonis, E., Morris, E., Knutton, S., Booy, F.P. and Frankel, G. (2003). 
3D Structure of EspA Filaments from Enteropathogenic Escherichia coli. 
Molecular Microbiology 49, 301–308. 
 88 
Deacon, V., Dziva, F., van Diemen, P.M., Frankel, G. and Stevens, M.P. (2010). 
Efa-1/LifA Mediates Intestinal Colonization of Calves by Enterohaemorrhagic 
Escherichia coli O26 : H-in a Manner Independent of Glycosyltransferase and 
Cysteine Protease Motifs or Effects on Type III Secretion. Microbiology 156, 
2527–2536. 
Deibel, C., Dersch, P. and Ebel, F. (2001). Intimin from Shiga Toxin-Producing 
Escherichia coli and its Isolated C-Terminal Domain Exhibit Different Binding 
Properties for Tir and a Eukaryotic Surface Receptor. International Journal of 
Medical Microbiology 290, 683–691. 
Deibel, C., Krämer, S., Chakraborty, T. and Ebel, F. (1998). EspE, a Novel Secreted 
Protein of Attaching and Effacing Bacteria, is Directly Translocated into 
Infected Host Cells, Where it Appears as a Tyrosine-Phosphorylated 90 kDa 
Protein. Molecular Microbiology 28, 463–474. 
Deng, W., de Hoog, C.L., Yu, H.B, Li, Y., Croxen, M.A., Thomas, N.A., Puente, J.L, 
Foster, L.J. and Finlay, B.B. (2010). A Comprehensive Proteomic Analysis of 
the Type III Secretome of Citrobacter rodentium. The Journal of Biological 
Chemistry 285, 6790–6800. 
Deng, W., Li, Y., Vallance, B.A. and Finlay, B.B. (2001). Locus of Enterocyte 
Effacement from Citrobacter rodentium: Sequence Analysis and Evidence for 
Horizontal Transfer Among Attaching and Effacing Pathogens. Infection and 
Immunity 69, 6323–6335. 
Deng, W., Yu, H.B., de Hoog, C.L., Stoynov, N., Li, Y., Foster, L.J. and Finlay, B.B. 
(2012). Quantitative Proteomic Analysis of Type III Secretome of 
Enteropathogenic Escherichia coli Reveals an Expanded Effector Repertoire for 




DeVinney, R., Puente, J.L., Gauther, A., Gossney, D. and Finlay, B.B. (2001). 
Enterohaemorrhagic and Enteropathogenic Escherichia coli use a Different 
Tir-based Mechanism for Pedestal Formation. Molecular Microbiology 41, 
1445–1458. 
DeVinney, R., Stein, M., Reinscheid, D., Abe, A., Ruschowski, S. and Finlay, B.B. 
(1999). Enterohemorrhagic Escherichia coli O157:H7 Produces Tir, which is 
Translocated to the Host Cell Membrane but is not Tyrosine Phosphorylated. 
Infection and Immunity 67, 2389–2398. 
Donnenberg, M.S., Girón, J.A., Nataro, J.P. and Kaper, J.B. (1992). A 
Plasmid-Encoded Type IV Fimbrial Gene of Enteropathogenic Escherichia coli 
Associated with Localized Adherence. Molecular Microbiology 6, 3427–3437. 
Donnenberg, M.S., Lai, L. and Taylor, K.A. (1997). The Locus of Enterocyte 
Effacement Pathogenicity Island of Enteropathogenic Escherichia coli Encodes 
Secretion Functions and Remnants of Transposons at its Extreme Right End. 
Gene 184, 107–114. 
Dziva, F., van Diemen P.M., Stevens, M.P., Smith, A.J. and Wallis T.S. (2004). 
Identification of Escherichia coli O157:H7 Genes Influencing Colonization of 
the Bovine Gastrointestinal Tract Using Signature-Tagged Mutagenesis. 
Microbiology 150, 3631–3645. 
Ebel, F., Podzadel, T., Rohde, M., Kresse, A.U., Krämer, S., Deibel, C., Guzmán, 
C.A. and Chakraborty, T. (1998). Initial Binding of Shiga Toxin-Producing 
Escherichia coli to Host Cells and Subsequent Induction of Actin 
Rearrangements Depend on Filamentous EspA-Containing Surface 
Appendages. Molecular Microbiology 30, 147–161. 
Edberg, S.C., Rice, E.W., Karlin, R.J. and Allen, M.J. (2000). Escherichia coli: the 
Best Biological Drinking Water Indicator for Public Health Protection. Journal 
of Applied Microbiology 88, 106–116. 
 90 
Eftink, M.R. and Ghiron, C.A. (1976). Exposure of Tryptophanyl Residues in 
Proteins. Quantitative Determination by Fluorescence Quenching Studies. 
Biochemisty 15, 672–680. 
Elliott, S.J., Wainwright, L.A., McDaniel, T.K., Jarvis, K.G., Deng, Y., Lai, L., 
McNamara, B.P., Donnenberg, M.S. and Kaper, J.B. (1998). The Complete 
Sequence of the Locus of Enterocyte Effacement (LEE) from Enteropathogenic 
Escherichia coli E2348/69. Molecular Microbiology 28, 1–4. 
Endo, Y., Tsurugi, K., Yutsudo, T., Takeda, Y., Ogasawara, T. and Igarashi, K. 
(1988). Site of Action of a Vero Toxin (VT2) from Escherichia coli O157:H7 
and of Shiga Toxin on Eukaryotic Ribosomes. European Journal of 
Biochemistry 50, 45–50. 
Epps, D.E., Raub, T.J., Caiolfa, V., Chiari, A. and Zamai, M. (1999). Determination 
of the Affinity of Drugs Toward Serum Albumin by Measurement of the 
Quenching of the Intrinsic Tryptophan Fluorescence of the Protein. The Journal 
of Pharmacy and Pharmacology 51, 41–48. 
Faust, M.A., Aotaky, A.E. and Hargadon, M.T. (1975). Effect of Physical Parameters 
on the In Situ Survival of Escherichia coli MC-6 in an Estuarine Environment. 
Applied Microbiology 30, 800–806. 
Filloux, A. (2010). Secretion Signal and Protein Targeting in Bacteria: A Biological 
Puzzle. Journal of Bacteriology 192, 3847–3849. 
Finlay, B.B., Rosenshine, I., Donnenberg, M.S. and Kaper J.B. (1992). Cytoskeletal 
Composition of Attaching and Effacing Lesions Associated with 
Enteropathogenic Escherichia coli Adherence to HeLa Cells. Infection and 
Immunity 60, 2541–2543. 
Folta-Stogniew, E. and Williams, K.R. (1999). Determination of Molecular Masses 
of Proteins in Solution: Implementation of an HPLC Size Exclusion 
Chromatography and Laser Light Scattering Service in a Core Laboratory. 
Journal of Biomolecular Techniques 10, 51–63. 
 91 
Foubister, V., Rosenshine, I., Donnenberg, M.S. and Finlay, B.B. (1994). The eaeB 
Gene of Enteropathogenic Escherichia coli is Necessary for Signal 
Transduction in Epithelial Cells. Infection and Immunity 62, 3038–3040. 
Frankel, G., Candy, D.C.A. Everest, P. and Dougan, G. (1994). Characterization of 
the C-Terminal Domains of Intimin-Like Proteins of Enteropathogenic and 
Enterohemorrhagic Escherichia coli, Citrobacter freundii, and Hafnia alvei. 
Infection and Immunity 62, 1835–1842. 
Frankel, G., Lider, O., Hershkoviz, R., Mould, A.P., Kachalsky, S.G., Candy, 
D.C.A., Cahalon, L., Humphries, M.J. and Dougan, G. (1996). The 
Cell-Binding Domain of Intimin from Enteropathogenic Escherichia coli Binds 
to β1-Integrins. The Journal of Biological Chemistry 271, 20359–20364. 
Fraser, M.E., Chernaia M.M., Kozlov, Y.V. and James, M.N.G. (1994). Crystal 
Structure of the Holotoxino from Shigella Dysenteriae at 2.5 Å Resolution. 
Nature Structural Biology 1, 59–64. 
Gao, X., Wang, X., Pham, T.H., Feuerbacher, L.A., Lubos, M., Huang, M., Olsen, 
R., Musheglan, A., Slawson, C. and Hardwidge, P.R. (2013). NleB, a Bacterial 
Effector with Glycosyltransferase Activity Targets GADPH Function to Inhibit 
NF-κB Activation. Cell Host and Microbe 13, 87–99. 
Garmendia, J., Phillips, A.D., Carlier, M., Chong, Y., Schüller, S., Marches, O., 
Dahan, S., Oswald, E., Shaw, R.K., Knutton, S. and Frankel, G. (2004). TccP is 
an Enterohaemorrhagic Escherichia coli O157:H7 Type III Effector Protein that 
Couples Tir to the Actin-Cytoskeleton. Cellular Microbiology 6, 1167–1183. 
Garred, Ø., van Deurs, B. and Sandvig, K. (1995). Furin-Induced Cleavage and 
Activation of Shiga Toxin. The Journal of Biological Chemistry 270, 10817–
10821. 
Gauthier, A., Robertson, M.L., Lowden, M., Ibarra, J.A., Puente, J.L. and Finlay, 
B.B. (2005). Transcriptional Inhibitor of Virulence Factors in Enteropathogenic 
Escherichia coli. Antimicrobial Agents and Chemotherapy 49, 4101–4109. 
 92 
Geddes, K., Cruz III, F. and Heffron, F., (2007). Analysis of Cells Targeted by 
Salmonella Type III Secretion in vivo. PLOS Pathogens 3, 2017–2028. 
Gerba, C.P. and McLeod, J.S. (1976). Effects of Sediments on the Survival of 
Escherichia coli in Marine Waters. Applied and Environmental Microbiology 
32, 114–120. 
Gerlach, R.G., Jäckel, D., Geymeier, N. and Hensel, M. (2007). Salmonella 
Pathogenicity Island 4-Mediated Adhesion is Coregulated with Invasion Genes 
in Salmonella enterica. Infection and Immunity 75, 4697–4709. 
Girón, J.A., Ho, A.S.Y and Schoolnik, G.K. (1991). An Inducible Bundle-Forming 
Pilus of Enteropathogenic Escherichia coli. Science 254, 710–713. 
Gobert, A.P., Vareille, M., Glasser, A., Hindré, T., de Sablet, T. and Martin, C. 
(2007). Shiga Toxin Produced by Enterohemorrhagic Escherichia coli Inhibits 
PI3K/NF-κB Signaling Pathway in Globotriaosylceramide-3-Negative Human 
Intestinal Epithelial Cells. Journal of Immunology 178, 8168–8174. 
Gomes, T.A.T., Vieira, M.A.M., Wachsmuth, I.K., Blake, P.A. and Trabulsi, L.R. 
(1989). Serotype-Specific Prevalence of Escherichia coli Strains with EPEC 
Adherence Factor Genes in Infants with and without Diarrhea in São Paulo, 
Brazil. The Journal of Infectious Diseases 160, 131–135. 
Goosney, D.L., DeVinney, R. and Finlay, B.B. (2001). Recruitment of Cytoskeletal 
and Signaling Proteins to Enteropathogenic and Enterohemorrhagic Escherichia 
coli Pedestals. Infection and Immunity 69, 3315–3322. 
Gruenheid, S., DeVinney, R., Bladt, F., Goosney, D., Gelkop, S., Gish, G.D., 
Pawson, T. and Finlay, B.B. (2001). Enteropathogenic E. coli Tir Binds Nck to 
Initiate Actin Pedestal Formation in Host Cells. Nature Cell Biology 3, 856–
859. 
 93 
Hacker, J., Blum-Oehler, G., Mühldorfer, I. and Tschäpe, H. (1997). Pathogenicity 
Islands of Virulent Bacteria: Structure, Function and Impact on Microbial 
Evolution. Molecular Microbiology 23, 1089–1097. 
Hauf, N. and Chakraborty, T. (2003). Suppression of NF-κB Activation and 
Proinflammatory Cytokine Expression by Shiga Toxin-Producing Escherichia 
coli. Journal of Immunology 170, 2074–2082. 
Hayashi, T., Makino, K., Ohnishi, M., Kurowaka, K., Ishii, K., Yokoyama, K., Han, 
C., Ohtsubo, E., Nakayama, K., Murata, T., Tanaka, M., Tobe, T., Iida, T., 
Takami, H., Honda, T., Sasakawa, C., Ogasawara, N., Yasunaga, T., Kuhara, S., 
Shiba, T., Hattori, M. and Shinagawa, H. (2001). Complete Genome Sequence 
of Enterohemorrhagic Escherichia coli O157:H7 and Genomic Comparison 
with a laboratory strain K-12. DNA Research : an International Journal for 
Rapid Publication of Reports on Genes and Genomes 8, 11–22. 
von Heijne, G. (1990). The Signal Peptide. Journal of Membrane Biology 115, 195–
201. 
Hemrajani, C., Berger, C.N., Robinson, K.S., Marchès, O., Mousnier, A. and 
Frankel, G. (2010). NleH Effectors Interact with Bax Inhibitor-1 to Block 
Apoptosis During Enteropathogenic Escherichia coli Infection. Proceedings of 
the National Academy of Sciences of the United States of America 107, 3129–
3134. 
Ho, N.K., Henry, A.C., Johnson-Henry, K. and Sherman, P.M. (2013). 
Pathogenicity, Host Responses and Implications for Management of 
Enterohemorrhagic Escherichia coli O157:H7 Infection. Canadian Journal of 
Gastroenterology 27, 281–5. 
Hoey, D.E.E., Sharp, L., Currie, C., Lingwood, C.A., Gally, D.L. and Smith D.G.E. 
(2003). Verotoxin 1 Binding to Intestinal Crypt Epithelial Cells Results in 
Localization to Lysosomes and Abrogation of Toxicity. Cellular Microbiology 
5, 85–97. 
 94 
Holmes, A., Mühlen, S., Roe, A.J. and Dean, P. (2010). The EspF Effector, a 
Bacterial Pathogen’s Swiss Army Knife. Infection and Immunity 78, 4445–
4453. 
Hudault, S., Guignot, J. and Servin, A.L. (2001). Escherichia coli Strains Colonising 
the Gastrointestinal Tract Protect Germfree Mice Against Salmonella 
typhimurium Infection. Gut, 49, 47–55. 
Hyland, R.M., Sun, J., Griener, T.P., Mulvey, G.L., Klassen, J.S., Donnenberg, M.S. 
and Armstrong, G.D. (2008). The Bundlin Pilin of Enteropathogenic 
Escherichia coli is an N-Acetyllactosamine-Specific Lectin. Cellular 
Microbiology 10, 177–187. 
Iguchi, A., Thomson, N.R., Ogura, Y., Saunders, D., Ooka, T., Henderson, I.R., 
Harris, D., Asadulghani, M., Kurokawa, K., Dean, P., Kenny, B., Quail, M.A., 
Thurston, S., Dougan, Hayashi, T., Parkhill, J. and Frankel, G. (2009). 
Complete Genome Sequence and Comparative Genome Analysis of 
Enteropathogenic Escherichia coli O127:H6 Strain E2348/69. Journal of 
Bacteriology 91, 347–354. 
Iizumi, Y., Sagara, H., Kabe, Y., Azuma, M., Kume, K., Ogawa, M., Nagai, T., 
Gillespe, P.G., Sasakawa, C. and Handa, H. (2007). The Enteropathogenic E. 
coli Effector EspB Facilitates Microvillus Effacing and Antiphagocytosis by 
Inhibiting Myosin Function. Cell Host and Microbe 2, 383–392. 
Jacewicz, M., Clausen, H., Nudelman, E., Donohue-Rolfe, A. Keusch, G.T. (1986). 
Pathogenesis of Shigella Diarrhea. XI. Isolation of a Shigella Toxin-Binding 
Glycolipid from Rabbit Jejunum and HeLa Cells and its Identification as 
Globotriaosylceramide. The Journal of Experimental Medicine 163, 1391–1404. 
Janka, A., Bielaszewska, M., Dobrindt, U. and Karch, H. (2002). Identification and 
Distribution of the Enterohemorrhagic Escherichia coli Factor for Adherence 
(efa1) Gene in Sorbitol-Fermenting Escherichia coli O157: H-. International 
Journal of Medical Microbiology : IJMM 292, 207–214. 
 95 
Jarvis, K.G., Girón, J.A., Jerse, A.E., McDaniel, T.K., Donnenberg, M.S. and Kaper, 
J.B. (1995). Enteropathogenic Escherichia coli Contains a Putative Type III 
Secretion System Necessary for the Export of Proteins Involved in Attaching 
and Effacing Lesion Formation. Proceedings of the National Academy of 
Sciences of the United States of America 92, 7996–8000. 
Jerse, A.E., Yu, J., Tall, B.D. and Kaper, J.B. (1990). A Genetic Locus of 
Enteropathogenic Escherichia coli Necessary for the Production of Attaching 
and Effacing Lesions on Tissue Culture Cells. Proceedings of the National 
Academy of Sciences of the United States of America 87, 7839–7843. 
Jiménez, L., Muñiz, I., Toranzos, G.A. and Hazen, T.C. (1990). Survival and 
Activity of Salmonella typhimurium and Escherichia coli in Tropical 
Freshwater. Journal of Bacteriology 67, 23–349. 
Johannes, L. and Römer, W. (2010). Shiga Toxins – From Cell Biology to 
Biomedical Applications. Nature Reviews Microbiology 8, 105–116. 
Johansen, B.K., Wasteson, Y., Granum, P.E. and Brynestad, S. (2001). Mosaic 
Structure of Shiga-Toxin-2-Encoding Phages Isolated from Escherichia coli 
O157:H7 Indicates Frequent Gene Exchange Between Lambdoid Phage 
Genomes. Microbiology 147, 1929–1936. 
Just, I., Wilm, M., Selzer, J., Rex, G., von Eichel-Streibert, C., Mann, M. and 
Aktories, K. (1995). The Enterotoxin from Clostridium difficile (ToxA) 
Monoglucosylates the Rho Proteins. The Journal of Biological Chemistry 270, 
13932–13936. 
Kelly, S.M., Jess, T.J. and Price, N.C. (2005). How to Study Proteins by Circular 




Kenny, B. (1999). Phosphorylation of Tyrosine 474 of the Enteropathogenic 
Escherichia coli (EPEC) Tir Receptor Molecule is Essential for Actin 
Nucleating Activity and is Preceded by Additional Host Modifications. 
Molecular Microbiology 31, 1229–1241. 
Kenny, B., Abe, A., Stein, M. and Finlay, B.B. (1997b). Enteropathogenic 
Escherichia coli Protein Secretion is Induced in Response to Conditions Similar 
to Those in the Gastrointestinal Tract. Infection and Immunity 65, pp.2606–
2612. 
Kenny, B., DeVinney, R., Stein, M., Reinscheid, D.J., Frey, E.A. Finlay, B.B. 
(1997a). Enteropathogenic E. coli (EPEC) Transfers its Receptor for Intimate 
Adherence into Mammalian Cells. Cell 91, 511–520. 
Klapproth, J.A. (2010). The Role of Lymphostatin/EHEC Factor for Adherence-1 in 
the Pathogenesis of Gram Negative Infection. Toxins 2, 954–962. 
Klapproth, J., Donnenberg, M.S., Abraham, J.M. and James, S.P. (1996). Products of 
Enteropathogenic E. coli Inhibit Lymphokine Production by Gastrointestinal 
Lymphocytes. The American Journal of Physiology 271, 841–848. 
Klapproth, J., Donnenberg, M.S, Abraham, J.M., Mobley, H.L.T. and James, S.P. 
(1995). Products of Enteropathogenic Escherichia coli Inhibit Lymphocyte 
Activation and Lymphokine Production. Infection and Immunity 63, 2248–
2254. 
Klapproth, J.A. Saskia, M. Sherman, M. Babbin, B. Donnenberg, M.S. Fernandes, 
P.J. Scaletsky, I.C.A. Kalman, D. Nusrat, A Williams, I., 2005. Citrobacter 
rodentium lifA/efa1 is Essential for Colonic Colonization and Crypt Cell 
Hyperplasia In Vivo. Infection and Immunity 73 pp.1441–1451. 
Klapproth, J.A., Scaletsky, I.C., McNamara, B., Lai, L., Malstrom, C., James, S.P. 
and Donnenberg, M.S. (2000). A Large Toxin from Pathogenic Escherichia coli 
Strains That Inhibits Lymphocyte Activation. Infection and Immunity 68, 2148–
2155. 
 97 
Knutton, S., Rosenhine, I., Pallen, M.J., Nisan, I., Neves, B.C., Bain, C., Wolff, C., 
Dougan, G. and Frankel, G. (1998). A Novel EspA-Associated Surface 
Organelle of Enteropathogenic Escherichia coli Involved in Protein 
Translocation into Epithelial Cells. The EMBO Journal 17, .2166–2176. 
Knutton, S., Shaw, R.K., Anantha, R.P., Donnenberg, M.S. and Zorgani, A.A. 
(1999). The Yype IV Bundle-Forming Pilus of Enteropathogenic Escherichia 
coli Undergoes Dramatic Alterations in Structure Associated with Bacterial 
Adherence, Aggregation and Dispersal. Molecular Microbiology 33, 499–509. 
Kresse, A.U., Beltrametti, F., Müller, A., Ebel, F. and Guzmán, C.A. (2000). 
Characterization of SepL of Enterohemorrhagic Escherichia coli. Journal of 
Bacteriology 182, 6490–6498. 
Kresse, A.U., Rohde, M. and Guzmán, C.A. (1999). The EspD Protein of 
Enterohemorrhagic Escherichia coli is Required for the Formation of Bacterial 
Surface Appendages and is Incorporated in the Cytoplasmic Membranes of 
Target Cells. Infection and Immunity 67, 4834–4842. 
Lai, L., Wainwright, L.A., Stone, K.D. and Donnenberg, M.S. (1997). A Third 
Secreted Protein that is Encoded by the Enteropathogenic Escherichia coli 
Pathogenicity Island is Required for Transduction of Signals and for Attaching 
and Effacing Activities in Host Cells. Infection and Immunity 65, 2211–2217. 
Law, H.T., Chua, M., Moon, K., Foster, L.J. and Guttman, J.A. (2015). Mass 
Spectrometry-Based Proteomics Identification of Enteropathogenic Escherichia 
coli Pedestal Constituents. Journal of Proteome Research 14, 2520–2527. 
Lea, N., Lord, J.M. and Roberts, L.M. (1999). Proteolytic Cleavage of the A Subunit 
is Essential for Maximal Cytotoxicity of Escherichia coli O157:H7 Shiga-Like 





Leimbach, A., Hacker, J. and Dobrindt, U. (2013). E. coli as an All-Rounder: The  
Thin Line Between Commensalism and Pathogenicity. Current Topics in 
Microbiology and Immunology vol. 358: Between Pathogenicity and 
Commensalism, pp.3 - 33. Springer Heildelberg, New York. 
Levine, M.M. and Edelman, R. (1984). Enteropathogenic Escherichia coli of Classic 
Serotypes Associated with Infant Diarrhea: Epidemiology and Pathogenesis. 
Epidemiological Reviews 6, 31–51. 
Levine, M.M., Bergquist, E.J., Nalin, D.R., Waterman, D.H., Hornick, R.B., Young, 
C.R. and Sotman, S. (1978). Escherichia coli Strains that Cause Diarrhoea but 
do not Produce Heat-Labile or Heat-Stable Enterotoxins and are Non-Invasive. 
The Lancet 1, 1119–1122. 
Levine, M.M., Nataro, J.P., Karch, H., Baldini, M.M., Kaper, J.B., Black, R.E., 
Clements, M.L. and O'Brien, A.D. (1985). The Diarrheal Response of Humans 
to Some Classic Serotypes of Enteropathogenic Escherichia coli is Dependent 
on a Plasmid Encoding an Enteroadhesiveness Factor. The Journal of Infectious 
Diseases, 152, 550–559. 
Li, L., Mendis, N., Trigui, H., Oliver, J.D. and Faucher, S.P. (2014). The Importance 
of the Viable but Non-Culturable State in Human Bacterial Pathogens. 
Frontiers in Microbiology 5, 1–20. 
Li, S., Zhang, L., Yoa, Q., Li, L., Dong, N., Rong, J., Gao, W., Ding, X., Sun, L., 
Chen, X., Chen, S. and Shao, F. (2013). Pathogen Blocks Host Death Receptor 
Signalling by Arginine GlcNAcylation of Death Domains. Nature 501, 242–
246. 
Lindberg, A., Brown, J.E, Strömberg, N., Westling-Ryd, M., Schultz J.E. and 
Karlsson, K. (1987). Identification of the Carbohydrate Receptor for Shiga 
Toxin Produced by Shigella dysenteriae Type 1. The Journal of Biological 
Chemistry 262, 1779–85. 
 99 
Lo, M.C., Aulabaugh, A., Jin, G., Cowling, R., Bard, J., Malamas, M. and Ellestad, 
G. (2004). Evaluation of Fluorescence-Based Thermal Shift Assays for Hit 
Identification in Drug Discovery. Analytical Biochemistry 332, 153–159. 
Lobley, A., Whitmore, L. and Wallace, B.A. (2002). DICHROWEB: an Interactive 
Website for the Analysis of Protein Secondary Structure from Circular 
Dichroism Spectra. Bioinformatics 18, 211–212. 
Madden, T. (2002). The BLAST Sequence Analysis Tool. The NCBI Handbook 
[Internet]. Bethesda (MD): National Center for Biotechnology Information 
(US). URL: http://www.ncbi.nlm.nih.gov/books/NBK21097/ 
Makino, K., Ishii, K., Yasunaga, T., Hattori, M., Yokoyama, K., Yutsudo, C.H., 
Kubota, Y. Yamaichi, Y., Iida, T., Yamamoto, K., Honda, T., Han, C., Ohtsubo, 
E., Kasamatsu, M., Hayashi, T., Kuhara, S. and Shinagawa, H. (1998). 
Complete Nucleotide Sequences of 93-kb and 3.3-kb Plasmids of an 
Enterohemorrhagic Escherichia coli O157:H7 Derived from Sakai Outbreak. 
DNA Research : an International Journal for Rapid Publication of Reports on 
Genes and Genomes 5, 1–9. 
Mallard, F., Antony, C., Tenza, D., Salamero, J., Goud, B. and Johannes, L. (1998). 
Direct Pathway from Early/Recycling Endosomes to the Golgi Apparatus 
Revealed Through the Study of Shiga Toxin B-Fragment Transport. Journal of 
Cell Biology 143, 973–990. 
Malstrom, C. and James, S. (199)8. Inhibition of Murine Splenic and Mucosal 
Lymphocyte Function by Enteric Bacterial Products. Infection and Immunity 66, 
3120–3127. 





Malyukova, I., Murray, K.F., Zhu, C., Boedeker, E., Kane, A., Patterson, K., 
Peterson, J.R., Donowitz, M. and Kovbasnjuk, O. (2009). Macropinocytosis in 
Shiga Toxin 1 Uptake by Human Intestinal Epithelial Cells and Transcellular 
Transcytosis. American Journal of Physiology Gastrointestinal and Liver 
Physiology, 21205, 78–92. 
Manjarrez-Hernandez, H.A., Baldwin, T.J., Aitken, A., Knutton, S. and Williams, 
P.H. (1992). Intestinal Epithelial Cell Protein Phophorylation in 
Enteropathogenic Escherichia coli Diarrhoea. The Lancet 339, 521–523. 
Maslon, M.M., Hrstka, R., Vojtesek, B. and Hupp, T.R. (2010). A Divergent 
Substrate-Binding Loop within the Pro-Oncogenic Protein Anterior Gradient-2 
Forms a Docking Site for Reptin. Journal of Molecular Biology 404, 418–438. 
McDaniel, T.K., Jarvis, K.G., Donnenberg, M.S. and Kaper, J.B. (1995). A Genetic 
Locus of Enterocyte Effacement Conserved Among Diverse Enterobacterial 
Pathogens. Proceedings of the National Academy of Sciences of the United 
States of America 92, 1664–1668. 
McNeilly, T.N., Mitchell, M.C., Rosser, T., McAteer, S., Low, J.C., Smith, D.G.E., 
Huntley, J.F., Mahajan, A. and Gally, D. (2010). Immunization of Cattle with a 
Combination of Purified Intimin-531, EspA and Tir Significantly Reduces 
Shedding of Escherichia coli O157:H7 Following Oral Challenge. Vaccine 28, 
1422–1428. 
Mellies, J.L. and Lorenzen, E. (2014). Enterohemorrhagic Escherichia coli Virulence 
Gene Regulation. Microbiology Spectrum 2. 
Mellies, J.L., Barron, A.M.S. and Carmona, A.M. (2007). Enteropathogenic and 
Enterohemorrhagic Escherichia coli Virulence Gene Regulation. Infection and 
Immunity 75, 4199–4210. 
 
 101 
Mellmann, A., Bielaszewska, M., Köck, R., Friedrich, A.W., Fruth, A., Middendorf, 
B., Harmsen, D., Schmidt, M.A. and Karch, H. (2008). Analysis of Collection 
of Hemolytic Uremic Syndrome-Associated Enterohemorrhagic Escherichia 
coli. Emerging Infectious Diseases 14, 1287–1290. 
Menge, C., Wieler, L.H., Schlapp, T. and Baljer, G. (1999). Shiga Toxin 1 from 
Escherichia coli Blocks Activation and Proliferation of Bovine Lymphocyte 
Subpopulations in vitro. Infection and Immunity 67, 2209–2217. 
Mills, E., Baruch, K., Aviv, G., Nitzan, M. and Rosenshine I. (2013). Dynamics of 
the Type III Secretion System Activity of Enteropathogenic Escherichia coli. 
mBio 4, 1–9. 
Morgan, E., Bowen, A.J., Carnell, S.C., Wallis, T.S. and Stevens, M.P. (2007). SiiE 
is Secreted by the Salmonella enterica Serovar Typhimurium Pathogenicity 
Island 4-Encoded Secretion System and Contributes to Intestinal Colonization 
in Cattle. Infection and Immunity 75, 1524–1533. 
Nadler, C., Baruch, K., Kobi, S., Mills, E., Haviv, G., Farago, M., Alkalay, I., 
Bartfeld, S., Meyer, T.F., Ben-Neriah, Y. and Rosenshine, I. (2010). The Type 
III Secretion Effector NleE Inhibits NF-κB Activation. PLOS Pathogens 6, 1–
11. 
Nataro, J.P.  and Kaper, J.B. (1998). Diarrheagenic Escherichia coli. Clinical 
Microbiology Reviews 11, 142–201. 
Nataro, J.P., Maher, K.O., Mackie, P. and Kaper, J.B. (1987). Characterization of 
Plasmids Encoding the Adherence Factor of Enteropathogenic Escherichia coli. 
Infection and Immunity 55, 2370–2377. 
Naylor, S.W., Roe, A.J., Nart, P., Spears, K., Smith, D.G.E., Low, J.C. and Gally, 
D.L. (2005). Escherichia coli O157:H7 Forms Attaching and Effacing Lesions 
at the Terminal Rectum of Cattle and Colonization Requires the LEE4 operon. 
Microbiology 151, 2773–2781. 
 102 
Neely, M.N. and Friedman, D.I. (1998). Functional and Genetic Analysis of 
Regulatory Regions of Coliphage H-19B: Location of Shiga-Like toxin and 
Lysis Genes Suggest a Role for Phage Functions in Toxin Release. Molecular 
Microbiology 28, 1255–1267. 
Nicholls, L., Grant, T.H. and Robins-Browne, R.M. (2000). Identification of a Novel 
Genetic Locus that is Required for in vitro Adhesion of a Clinical Isolate of 
Enterohaemorrhagic Escherichia coli to Epithelial Eells. Molecular 
Microbiology 35, 275–288. 
O’Brien, A.D., Newland, J.W., Miller, S.F., Holmes, R.K., Smith, H.W. and Formal, 
S.B. (1983). Shiga-Like Toxin-Converting Phage from Escherichia coli Strains 
That Cause Hemorrhagic Colitis or Infantile Diarrhea. Science 226, 694–696. 
Ochoa, T.J. and Contreras, C.A. (2011). Enteropathogenic E. coli (EPEC) Infection 
in Children. Current Opinion in Infectious Disease 24, 478–483. 
O’Connell, C.B., Creasey, E.A., Knutton, S., Elliot, S., Crowther, L.J., Luo, W., 
Albert, M.J., Kaper, J.B., Frankel, G. and Donnenberg, M.S. (2004). SepL, a 
Protein Required for Enteropathogenic Escherichia coli Type III Translocation, 
Interacts with Secretion Component SepD. Molecular Microbiology 52, 1613–
1625. 
Ogura, Y., Ooka, T., Iguchi, A., Toh, H., Asadulghani, M., Oshima, K., Kodama, T., 
Abe, H., Nakayama, K., Kurokawa, K., Tobe, T., Hattori, M. and Hayashi, T. 
(2009). Comparative Genomics Reveal the Mechanism of the Parallel Evolution 
of O157 and Non-O157 Enterohemorrhagic Escherichia coli. Proceedings of 
the National Academy of Sciences of the United States of America 106, 17939–
17944. 
Pacheco, A.R. and Sperandio, V. (2012). Shiga Toxin in Enterohemorrhagic E. coli: 
Regulation and Novel Anti-Virulence Strategies. Frontiers in Cellular and 
Infection Microbiology 2, 1–12. 
 
 103 
Pantoliano, M.W. Petrella, E.C. Kwasnoski, J.D. Lobanov, V.S. Myslik, J. Graf, E. 
Carver, T Asel, E. Springer, B.A. Lane, P. and Salemme, F.R. 2001. 
High-Density Miniaturized Thermal Shift Assays as a General Strategy for 
Drug Discovery. Journal of Biomolecular Screening 6, 429–440. 
Pearson, J.S., Glogha, C., Ong, S.Y., Kennedy, C.L., Kelly, M., Robinson, K.S., 
Lung, T.W.F., Mansel, A., Riedmaler, P., Oates, C.V.L., Zaid, A., Mühlen, S., 
Crepin, V.F., Marches, O., Ang, C., Williamson, N.A., O'Reilly, L.A., 
Bankovaki, A., Nachbur, U., Infusini, G., Webb, A.I., Silke, J., Strasser, A., 
Frankel, G. and Hartland, E.L. (2013). A Type III Effector Antagonizes Death 
Receptor Signalling During Bacterial Gut Infection. Nature 501, pp.247–51. 
Pearson, J.S., Riedmaier, P., Marchès, O., Frankel, G. and Hartland, E.L. (2011). A 
Type III Effector Protease NleC from Enteropathogenic Escherichia coli 
Targets NF-κB for Degradation. Molecular Microbiology 80, 219–230. 
Perna, N.T., Plunkett III, G., Burland, V., Mau, B., Glasner, J.D., Rose, D.J., 
Mayhew, G.F., Evans, P.S., Gregor, J., Kirkpatrick, H.A., Pósfai, G., Hackett, 
J., Klink, S., Boutin, A., Shao, Y., Miller, L., Grotbeck, E.J., Davis, N.W., Lim, 
A., Dimalanta, E.T., Potamousis, K.D., Apodaca, J., Anantharaman, T.S., Lin, 
J., Yen, G., Schwartz, D.C., Welch, R.A. and Blattner F.R (2001). Genome 
Sequence of Enterohaemorrhagic Escherichia coli O157: H7. Nature 409, 529–
533. 
Pierard, D., Huyghens, L. and Lauwers, S. (1991). Diarrhoea Associated with 
Escherichia coli Producing Porcine Oedema Disease Verotoxin. The Lancet 
338, 762. 
Price, N.C. and Nairn, J. (2009). Spectroscopic Methods to Study Secondary and 
Tertiary Structure. Exploring Proteins, pp.358 - 365. Oxford University Press 
Inc., New York. 
Promega (2009). CytoTox-ONETM Homogenous Membrane Integrity Assay Technical 
Bulletin. 
 104 
Promega (2012). CellTitre 96® AQueous One Solution Cell Proliferation Assay 
Technical Bulletin. 
Pruimboom-Brees, I.M., Morgan, T.W., Ackermann, M.R., Nystrom, E.D., Samuel, 
J.E., Cornick, N.A. and Moon, H.W. (2000). Cattle Lack Vascular Receptors for 
Escherichia coli O157:H7 Shiga Toxins. Proceedings of the National Academy 
of Sciences of the United States of America 97, 10325–10329. 
Pruitt, R.N., Chumbler, N.M., Rutherford, S.A., Farrow, M.A., Friedman, D.B, 
Spiller, B. and Lacy, D.B. (2012). Structural Determinants of Clostridium 
difficile Toxin A Glucosyltransferase Activity. The Journal of Biological 
Chemistry 287, 8013–8020. 
Puente, J.L., Bieber, D., Ramer, S.W., Murray, W. and Schoolnik, G.K. (1996). The 
Bundle-Forming Pili of Enteropathogenic Escherichia coli: Transcriptional 
Regulation by Environmental signals. Molecular Microbiology 20, 87–100. 
Rasko, D.A., Moreira, C.G., Li, D.R., Reading, N.C., Ritchie, J.M., Waldor, M.K., 
William, N., Taussig, R., Wei, S., Roth, M., Hughes, D.T., Huntley, J.F., Fina, 
M.W., Falck, J.R. and Sperandio, V. (2008). Targeting QseC Signaling and 
Virulence for Antibiotic Development. Science 321, 1078–1080. 
Reineke, J., Tenzer, S., Rupnik, M., Koschinski, A., Hasselmayer, O., Schrattenholz, 
A., Schild, H. and von Eichel-Streiber, C. (2007). Autocatalytic Cleavage of 
Clostridium difficile Toxin B. Nature 446, 415–419. 
Reissbrodt, R., Rienaecker, I., Romanova, J.M., Freestone, P.P.E., Haigh, R.D., Lyte, 
M., Tschäpe, H. and Williams, P.H. (2002). Resuscitation of Salmonella 
enterica Serovar Typhimurium and Enterohemorrhagic Escherichia coli from 
the Viable but Nonculturable State by Heat-Stable Enterobacterial Autoinducer. 
Applied and Environmental Microbiology 68, 4788–4794. 
Rivera, S.C., Hazen, T.C. and Toranzos, G.A. (1988). Isolation of Fecal Coliform 
from Pristine Sites in a Tropical Rain Forest. Applied and Environmental 
Microbiology 54, 513–517. 
 105 
Römer, W., Berland, L., Chambon, V., Gaus, K., Windschiegl, B., Tenza, D., Aly, 
M.R.E., Fraisier, V., Florent, J., Perrais, D., Lamaze, C., Raposo, G., Steinem, 
C., Sens, P., Bassereau, P. and Johannes, L. (2007). Shiga Toxin Induces 
Tubular Membrane Invaginations for its Uptake into Cells. Nature 450, 670–
675. 
Rosenshine, I., Donnenberg, M.S., Kaper, J.B. and Finlay, B.B. (1992). Signal 
Transduction Between Enteropathogenic Escherichia coli (EPEC) and 
Epithelial Cells: EPEC Induces Tyrosine Phosphorylation of Host Cell Proteins 
to Initiate Cytoskeletal Rearrangement and Bacterial Uptake. The EMBO 
Journal 11, 3551–3560. 
Rosenshine, I., Ruschkowski, S. and Finlay, B.B. (1996). Expression of 
Attaching/Effacing Activity by Enteropathogenic Escherichia coli Depends on 
Growth Phase, Temperature, and Protein Synthesis upon Contact with Epithelial 
Cells. Infection and Immunity 64, 966–973. 
Rosqvist, R., Magnusson, K.E. and Wolf-Watz, H. (1994). Target Cell Contact 
Triggers Expression and Polarized Transfer of Yersinia YopE Cytotoxin into 
Mammalian Cells. The EMBO Journal 13, 964–972. 
Saldaña, Z., Erdem, A.L., Schüller, S., Okeke, I.N., Lucas, M., Sivananthan, A., 
Phillips, A.D., Kaper, J.B., Puente, J.L. and Girón, J.A. (2009). The Escherichia 
coli Common Pilus and the Bundle-Forming Pilus Act in Concert During the 
Formation of Localized Adherence by Enteropathogenic E. coli. Journal of 
Bacteriology 191, 3451–3461. 
Sandvig, K., Garred, Ø., Prydz, K., Kozlov, J.V., Hansen, S.T. and van Deurs, B. 
(1992). Retrograde Transport of Endocytosed Shiga Toxin to the Endoplasmic 
Reticulum. Nature 358, 510–512. 
Sandvig, K., Olsnes, S., Brown, J.E., Peterson, O.W. and van Deurs, B. (1989). 
Endocytosis from Coated Pits of Shiga Toxin: A Glycolipid-Binding Protein 
from Shigella dysenteriae 1. Journal of Cell Biology 108, 1331–1343. 
 106 
Sanger, J.M., Chang, R., Ashton, F., Kaper, J.B. and Sanger, J.W. (1996). Novel 
Form of Actin-Based Motility Transports Bacteria on the Surface of Infected 
Cells. Cell Motilily and the Cytoskeleton 34, 279–287.  
Savageau, M.A. (1983). Esherichia coli Habitats, Cell Types, and Molecular 
Mechanisms of Gene Control. The American Naturalist, 122, 732–744. 
Savkovic, S.D., Koutsouris, A. and Hecht, G.. (1997). Activation of NF-κB in 
Intestinal Epithelial Cells by Enteropathogenic Escherichia coli. The American 
Journal of Physiology 273, 1160–1167. 
Schirmer, J. & Aktories, K. (2004). Large Clostridial Cytotoxins: Cellular Biology of 
Rho/Ras-Glucosylating toxins. Biochimica et Biophysica Acta - General 
Subjects 1673, 66–74. 
Schüller, S., Frankel, G. and Phillips, A.D. (2004). Interaction of Shiga Toxin from 
Escherichia coli with Human Intestinal Epithelial Cell Lines and Explants: Stx2 
Induces Epithelial Damage in Organ Culture. Cellular Microbiology 6, 289–
301. 
Selzer, J., Hofmann, Rex, G., Wilm, M., Mann, M., Just, I. and Aktories (1996). 
Clostridium novyi α-Toxin-Catalyzed Incorporation of GlcNAc into Rho 
Subfamily Proteins. The Journal of Biological Chemistry 271, 25173–25177. 
Shao, F., Meritt, P.M., Bao, Z., Innes, R.W. and Dixon, J.E. (2002). A Yersinia 
Effector and a Pseudomonas Avirulence Protein Define a Family of Cysteine 
Proteases Functioning in Bacterial Pathogenesis. Cell 109, 575–588. 
Shaw, R.K., Cleary, J., Murphy, M.S., Frankel, G. and Knutton, S. (2005). 
Interaction of Enteropathogenic Escherichia coli with Human Intestinal 
Mucosa: Role of Effector Proteins in Brush Border Remodeling and Formation 
of Attaching and Effacing Lesions. Infection and Immunity 73, 1243–1251. 
 
 107 
Sinclair, J.F. and O’Brien, A.D. (2002). Cell Surface-Localized Nucleolin is a 
Eukaryotic Receptor for the Adhesin Intimin-γ of Enterohemorrhagic 
Escherichia coli O157:H7. The Journal of Biological Chemistry 277, 2876–
2885. 
Sinclair, J.F. and O’Brien, A.D. (2004). Intimin Types α, β, and γ Bind to Nucleolin 
with Equivalent Affinity but Lower Avidity than to the Translocated Intimin 
Receptor. The Journal of Biological Chemistry 279, 33751–33758. 
Sohel, I., Puente, J.L., Ramer, S.W., Bieber, D., Wu, C. and Schoolnik, G.K. (1996). 
Enteropathogenic Escherichia coli: Identification of a Gene Cluster Coding for 
Bundle-Forming Pilus Morphogenesis. Journal of Bacteriology 178, 2613–
2628. 
Solo-Gabriele, H.M., Wolfert, M.A., Desmarais, T.R. and Palmer, C.J. (2000). 
Sources of Escherichia coli in a Coastal Subtropical Environment. Applied and 
Environmental Microbiology 66, 230–237. 
Stein, P.E., Boodhoo, A., Tyrrell, G.J., Brunton, J.L. and Read, R.J. (1992). Crystal 
Structure of the Cell-Binding B Oligomer of Verotoxin-1 from E. coli. Nature, 
355, 748–750. 
Stevens, M.P. & Frankel, G.M. (2014). The Locus of Enterocyte Effacement and 
Associated Virulence Factors of Enterohemorrhagic Escherichia coli. 
Microbiology Spectrum 2. 
Stevens, M.P., Roe, A.J., Vlisidou, I., van Diemen, P.M., La Ragione, R.M., Best, 
A., Woodward, M.J., Gally, D.I. and Wallis, T.S. (2004). Mutation of toxB and 
a Truncated Version of the efa-1 Gene in Escherichia coli O157: H7 Influences 
the Expression and Secretion of Locus of Enterocyte Effacement-Encoded 




Stevens, M.P., van Diemen, P.M., Frankel, G., Phillips, A.D. and Wallis, T.S. 
(2002). Efa1 Influences Colonization of the Bovine Intestine by Shiga 
Toxin-Producing Escherichia coli serotypes O5 and O111. Infection and 
Immunity 70, 5158–5166. 
Stone, K.D., Zhang, H., Carlson, L.K. and Donnenberg, M.S. (1996). A Cluster of 
Fourteen Genes from Enteropathogenic Escherichia coli is Sufficient for the 
Biogenesis of a Type IV Pilus. Molecular Microbiology 20, 325–337. 
Strom, M.S. and Lory, S. (1993). Structure-Function and Biogenesis of the Type IV 
Pili. Annual Review of Microbiology 47, 565–596. 
Tam, P.J. and Lingwood, C.A. (2007). Membrane-Cytosolic Translocation of 
Verotoxin A1 Subunit in Target Cells. Microbiology 153, 2700–2710. 
Tatsuno, I., Horie, M., Abe, H., Miki, T., Makino, K., Shinagawa, H., Tagucji, H., 
Kamiya, S., Hayashi, T. and Sasakawa, C. (2001). Gene on pO157 of 
Enterohemorrhagic Escherichia coli O157:H7 is Required for Full Epithelial 
Cell Adherence Phenotype. Infection and Immunity 69, 6660–6669. 
Taylor, J. (1970). Infectious Infantile Enteritis, Yesterday and Today. Section of 
Epidemiology & Preventive Medicine 63, 1297–1301. 
Taylor, K.A., O'Connell, C.B., Luther, P.W. and Donnenberg, M.S. (1998). The 
EspB Protein of Enteropathogenic Escherichia coli is Targeted to the 
Cytoplasm of Infected HeLa Cells. Infection and Immunity 66, 5501–5507. 
Temple, K.L., Camper, A.K. and McFeters, G.A. (1980). Survival of Two 
Enterobacteria in Feces Buried in Soil Under Field Conditions. Applied and 
Environmental Microbiology 40, 794–797. 
Thanabalasuriar, A., Koutsouris, A., Weflen, A., Mimee, M., Hecht, G. and 
Gruenheid, S. (2011). The Bacterial Virulence Factor NleA is Required for the 
Disruption of Intestinal Tight Junxtions by Enteropathogenic E. coli. Cell, 12, 
31–41. 
 109 
Tobe, T., Schoolnik, G.K., Sohel, I., Bustamante, V.H. and Puente, J.L. (1996). 
Cloning and Characterization of bfpTVW, Genes Required for the 
Transcriptional Activation of bfpA in Enteropathogenic Escherichia coli. 
Molecular Microbiology 21, 963–975. 
Toshima, H., Yoshimura, A., Arikawa, K., Hidaka, A., Ogasawara, J., Hase, A., 
Masaki, H. and Nishikawa, Y. (2007). Enhancement of Shiga Toxin Production 
in Enterohemorrhagic Escherichia coli Serotype O157:H7 by DNase Colicins. 
Applied and Environmental Microbiology 73, 7582–7588. 
Tozzoli, R., Caprioli, A. and Morabito, S. (2005). Detection of toxB, a Plasmid 
Virulence Gene of Escherichia coli O157, in Enterohemorrhagic and 
Enteropathogenic E. coli. Journal of Clinical Microbiology 43, 4052–4056. 
Trabulsi, L.R., Keller, R. and Gomes, T.A.T. (2002). Typical and Atypical 
Enteropathogenic Escherichia coli. Emerging Infectious Diseases 8, 508–513. 
Tree, J.J., Wang, D., McInally, C., Mahajan, A., Layton, A., Houghton, I., Elofsson, 
M., Stevens, M.P., Gally, D.L. and Roe, A.J. (2009). Characterization of the 
Effects of Salicylidene Acylhydrazide Compounds on Type III Secretion in 
Escherichia coli O157:H7. Infection and Immunity 77, 4209–4220. 
Triadafilopoulos, G., Pothoulakis, C., O'Brien, M.J. and LaMont, J.T. (1987). 
Differential Effects of Clostridium difficile toxins A and B on Rabbit Ileum. 
Gastroenterology 93, 273–279. 
Veenendaal, A.K.J., Sundin, C. and Blocker, A.J. (2009). Small-Molecule Type III 
Secretion System Inhibitors Block Assembly of the Shigella Type III Secreton. 
Journal of Bacteriology 191, 563–570. 
Vlisidou, I., Dziva, F., la Ragione, R.M., Best, A., Garmendia, J., Hawes, P., 
Monaghan, P., Cawthraw, S.A., Frankel, G., Woodward, M.J. and Stevens, M.P. 
(2006). Role of Intimin-Tir Interactions and the Tir-Cytoskeleton Coupling 
Protein in the Colonization of Calves and Lambs by Eschenchia coli O157:H7. 
Infection and Immunity 74, 758–764. 
 110 
Voulhoux, R., Ball, G., Ize, B., Vasil, M.L., Lazdunski, A., Wu, L. and Filloux, A. 
(2001). Involvement of the Twin-Arginine Translocation System in Protein 
Secretion via the Type II Pathway. The EMBO Journal 20, pp.6735–6741. 
Wachter, C., Beinke, C., Mattes, M. and Schmidt, M.A. (1999). Insertion of EspD 
into Epithelial Target Cell Membranes by Infecting Enteropathogenic 
Escherichia coli. Molecular Microbiology 31, 1695–1707. 
Wang, D., Roe, A.J., McAteer, S., Shipston, M.J. and Gally, D.L. (2008). Hierarchal 
Type III Secretion of Translocators and Effectors from Escherichia coli 
O157:H7 Requires the Carboxy Terminus of SepL that Binds to Tir. Molecular 
Microbiology 69, 1499–1512. 
Warawa, J., Finlay, B.B. and Kenny, B. (1999). Type III Secretion-Dependent 
Hemolytic Activity of Enteropathogenic Escherichia coli. Infection and 
Immunity 67, 5538–5540. 
Weljie, A.M. and Vogel, H.J. (2000). Tryptophan Fluorescence of Calmodulin 
Binding Domain Peptides Interacting with Calmodulin Containing Unnatural 
Methionine Analogues. Protein Engineering 13, 59–66. 
Winfield, M.D. and Groisman, E.A. (2003). Role of Nonhost Environments in the 
Lifestyles of Salmonella and Escherichia coli. Applied and Environmental 
Microbiology 69, 3687–3694. 
Wolff, C., Nisan, I., Hanski, E., Frankel, G. and Rosenshine, I. (1998). Protein 
Translocation into host Epithelial Cells by Infecting Enteropathogenic 
Escherichia coli. Molecular Microbiology 28, 143–155. 
Wu, B., Skarina, T., Yee, A., Jobin, M., DiLeo, R., Semesi, A., Fares, C., Lemak, A., 
Coombes, B.K., Arrowsmith, C.H., Singer, A.U. and Savchenko, A. (2010). 
NleG Type 3 Effectors from Enterohaemorrhagic Escherichia coli are U-Box 
E3 Ubiquitin Ligases. PLOS Pathogens 6, 1–17. 
 111 
Xie, G., Bonner, C.A. and Jensen, R.A. (2002). Dynamic Diversity of the 
Tryptophan Pathway in Chlamydiae: Reductive Evolution and a Novel Operon 
for Tryptophan Recapture. Genome Biology 3, 1–17. 
Yu, J. and Kaper, J.B. (1992). Cloning and Characterization of the eae Gene of 
Enterohaemorrhagic Escherichia coli O157:H7. Molecular Microbiology 6, 
411–417. 
Zhang, H. and Donnenberg, M.S. (1996). DsbA is Required for Stability of the Type 
IV Pilin of Enteropathogenic Escherichia coli. Molecular Microbiology 21, 
787–797. 
Zhang, H., Lory, S. and Donnenberg, M.S. (1994). A Plasmid-Encoded Prepilin 
Peptidase Gene from Enteropathogenic Escherichia coli. Journal of 
Bacteriology 176, 6885–6891. 
Zhang, X., McDaniel, A.D., Wolf, L.E., Keusch, G.T., Waldor, M.K. and Acheson, 
D.W.K. (2000). Quinolone Antibiotics Induce Shiga Toxin-Encoding 
Bacteriophages, Toxin Production, and Death in Mice. The Journal of Infectious 















Appendix 1: Composition of buffers and reagents 
 
TRIS buffer was composed of 50mL distilled water (dH2O) with 1.5M TRIS base 
buffer and made up to pH 8.8 using NaOH and HCl. 
 
To make 300mL of NZY+ broth, 2g of NZ amine, 1g of yeast extract and 1g of NaCl 
was dissolved in dH2O and made up to pH 7.5 using NaOH and HCl. The media was 
autoclaved then 2.5mL of sterile 1M MgCl and 1M MgSO4 was added along with 
0.4% (w/v) glucose. 
 
IMAC buffer A was composed of 500mL dH2O with 20mM NaH2PO4, 300mM 
NaCl, 5% (v/v) glycerol and 0.1% (v/v) Tween 20. It was made up to pH 7.8 using 
NaOH and HCl and 1mM fresh DTT was added before use. It was kept on ice or at 
6°C when not in use. 
 
IMAC buffer B was composed of 200mL dH2O with 20mM NaH2PO4, 5% (v/v) 
glycerol, 0.1% (v/v) Tween 20 and 500mM imidazole. It was made up to pH 7.8 
using NaOH and HCl and 1mM fresh DTT was added before use. It was kept on ice 
or at 6°C when not in use. 
 
The low salt buffer used for SEC was composed of 200mL dH2O with 10mM 
NaH2PO4, 50mM NaCl, 5% (v/v) glycerol and 0.025% (v/v) Tween 20. It was made 
up to pH 7.8 using NaOH and HCl and 1mM fresh DTT was added before use. It was 
kept on ice or at 6°C when not in use. 
 
The low salt buffer used for ion exchange chromatography was composed of 200mL 
dH2O with 10mM NaH2PO4, 1mM NaCl, 5% (v/v) glycerol and 0.025% (v/v) Tween 
20. It was made up to pH 7.8 using NaOH and HCl and 1mM fresh DTT was added 
before use. It was kept on ice or at 6°C when not in use. 
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Assay buffer was composed of 200mL of dH2O with 15mM NaH2PO4, 150mM NaCl 
and 5% (v/v) glycerol. It was made up to pH 7.8 using NaOH and HCl and 1mM 
fresh DTT was added before use. It was kept on ice or at 6°C when not in use. 
 
CD buffer was composed of 200mL of dH2O with 15mM NaH2PO4, 150mM NaF 
and 5% (v/v) glycerol. It was made up to pH 7.6 using NaOH and HCl and 1mM 
fresh DTT was added before use. It was kept on ice or at 6°C when not in use. 
 
Red blood cell lysis buffer was composed of 1L dH2O with 100mM KHCO3, 1.5mM 
NH4Cl and 10mM EDTA. It was made up to pH 8 using NaOH and HCl split into 
10 x 100mL aliquots and autoclaved. 
 
WT LifA buffer is the buffer that WT LifA was in after being filtered through the 
desalt column. It contains 15mM NaH2PO4, 180mM NaCl, 1mM DTT, 10% (v/v) 
glycerol and 0.05% Tween 20 in dH2O. 
 
DXD-AAA LifA buffer is the buffer that DXD-AAA LifA was in after being filtered 
through the desalt column. It contains 10mM NaH2PO4, 180mM NaCl, 1mM DTT, 
20% (v/v) glycerol and 0.025% Tween 20 in dH2O. 
 114 
Appendix 2: Nucleotide sequence of the DXD-AAA lifA gene 
 



























































































































































































































Appendix 3: Relevant published papers 
 
The following published paper incorporates work from this thesis. This paper is 
included with the author’s permission. It was published in The Journal of Biological 
Chemistry, January 2016. The paper can also be found at: 
http://www.jbc.org/content/early/2016/01/20/jbc.M115.709600.full.pdf+html?sid=14
b9bc92-1284-4a90-a991-b79e370db717. 
